Published in final edited form as:

Nat Rev Dis Primers. ; 1: 15010. doi:10.1038/nrdp.2015.10.

Cystic fibrosis

Felix Ratjen¹, Scott C. Bell², Steven M. Rowe³, Christopher H. Goss⁴, Alexandra L. Quittner⁵, Andrew Bush⁶

¹Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto M5G 1X8, Canada.

²Department of Thoracic Medicine, Queensland Children's Medical Research Institute, Brisbane, QLD, Australia.

³Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

⁴Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, WA, USA.

⁵Department of Psychology, University of Miami, Miami, FL, USA.

⁶Paediatrics Section, Imperial College, Paediatric Respiriology, National Heart and Lung Institute, and the Royal Brompton Harefield NHS Foundation Trust, London, UK.

Abstract

Cystic fibrosis is an autosomal-recessive, monogenetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene. The gene defect was first described 25 years ago and much progress has been made since then in our understanding on how *CFTR* mutations cause disease and how this can be addressed therapeutically. *CFTR* is a transmembrane protein that transports ions across the surface of epithelial cells. *CFTR* dysfunction affects many organs; however, lung disease is responsible for the vast majority of morbidity and mortality in patients with cystic fibrosis. Prenatal diagnostics, newborn screening and new treatment algorithms are changing the incidence and prevalence of the disease. Until recently, the standard of care in cystic fibrosis treatment focused on preventing and treating complications of the disease; now, novel treatment strategies targeting the ion channel abnormality directly are becoming available and it will be important to evaluate how these treatments affect disease progression and quality of life of patients. In this Primer, we summarize the current knowledge and provide an outlook on how cystic fibrosis clinical care and research will be affected by new knowledge and therapeutic options in the near future.

Cystic fibrosis is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene. Close to 2,000 mutations in this gene have been described to date (<http://genet.sickkids.on.ca/cftr/app>), although fewer than 150 are known to be disease causing (<http://cftr2.org>). Although cystic fibrosis is a monogenetic

Correspondence to: F.R. felix.ratjen@sickkids.ca.

Author contributions

Introduction (F.R.); Epidemiology (C.H.G.), Mechanisms/pathophysiology (S.M.R., S.C.B.); Diagnosis, screening and prevention (A.B., F.R., S.M.R.); Management (S.C.B., F.R.); Quality of life (A.L.Q.); Outlook (F.R., A.B.); overview of the Primer (F.R.).

disease, its phenotypic variability is substantial — as evidenced by the broad spectrum of disease severity observed in patients with the same genotype¹. The cystic fibrosis phenotype (Box 1) is characterized by progressive lung disease, exocrine pancreatic insufficiency that results in gastrointestinal malabsorption, intestinal abnormalities that result in malnutrition, impaired growth and a variety of other manifestations, including sinusitis and diabetes. CFTR primarily acts as a chloride channel that transports ions across the apical membrane of epithelial cells throughout the body, but has other functions, including bicarbonate secretion and inhibition of sodium transport, which are important for the pathophysiology of CFTR deficiency and dysfunction. Mutations in *CFTR* are grouped in classes that reflect their functional consequences; those leading to loss of CFTR expression on the cell surface or loss of its function are generally ‘severe’ mutations associated with a phenotype of both lung disease and pancreatic insufficiency. Mutations with residual CFTR function are often associated with preserved pancreatic function; some individuals exhibit single-organ manifestations, such a congenital bilateral absence of the vas deferens in the male reproductive tract². *CFTR* mutations have also been described in patients with cystic fibrosis-like organ manifestations — including pancreatitis, sinusitis or ‘idiopathic’ bronchiectasis (widening of the airways) — and the threshold of CFTR function needed to prevent disease varies between different organs^{3, 4}.

The discovery of the cystic fibrosis gene defect in 1989 has resulted in a better understanding of disease pathophysiology, but only in the past few years has this information led to targeted therapies that address the underlying cellular defect^{5–7}. Important advances in addressing all aspects of the disease have been made over the past two decades and the prognosis of patients with cystic fibrosis is constantly improving. The development of clinical trial networks has enabled rapid testing of putative treatments through training of research staff, establishment of standard operating procedures and reference laboratories. Strong partnerships have also been developed between government agencies, academic centers, voluntary health organizations, individuals and families with cystic fibrosis. Although these advances can largely be attributed to improvements in symptom-directed therapy of downstream complications, it is expected that upstream, CFTR-directed therapy will further improve patients’ longevity and quality of life. Here, we summarize the current understanding about how *CFTR* mutations cause disease, and outline current diagnostic strategies and therapeutic interventions addressing disease manifestations. We also describe the epidemiology of cystic fibrosis and how cystic fibrosis and its treatment affect patients’ quality of life. Lastly, we discuss how cystic fibrosis care and treatment is expected to change in future years.

Epidemiology

Changing diagnostic criteria and methods as well as improvements in clinical outcome have influenced the epidemiology of cystic fibrosis. Estimates of disease incidence are around one in 3,000 live births in persons of northern European descent^{8, 9}, with Ireland having the highest incidence at one in 1,400 live births¹⁰. Incidence varies by race and ethnicity; only one in 4,000 to 10,000 Latin Americans and one in 15,000 to 20,000 African Americans have cystic fibrosis, with even lower incidence rates in people of Asian background⁹. These estimates are based on information from western countries — epidemiological data are

missing for large regions of the world, including the Middle East, Asia and Africa. Importantly, some small populations in eastern Europe have very high incidence rates, specifically Albania, where the incidence was noted to be one in 555 (Ref¹¹). This high incidence is also reflected in data noting very high incidence in Albanian immigrants to northern Italy¹². The introduction of prenatal genetic screening in western countries seems to be correlated with decreasing incidence in some countries¹³. Although the incidence is decreasing, data from registries suggests that the prevalence is increasing because of improvements in survival (Figure 1)^{14–16}.

Recent analyses in the United States have demonstrated that cystic fibrosis survival improved in the period of 2000–2010 at a rate of 1.8% per year (95% CI 0.5–2.7%) and that the projected median survival of children born today is 56 years (95% CI 54–58 years) if the mortality rate continues to decrease at this rate¹⁵. However, median age of death is still in the mid-twenties to early thirties¹⁶. These data mirror earlier findings from the United Kingdom¹⁷. In concert with improved survival, the diagnosis of cystic fibrosis has moved to early in life with universal newborn screening in many countries. In 2010, over half (58%) of people with cystic fibrosis in the United States were diagnosed by newborn screening compared with only 8% of those diagnosed in 2000. A number of countries are now reporting that >50% of their cystic fibrosis population is >18 years of age^{18, 19}. Not only has the patient population aged, but an increasing number of people with mild phenotypes of cystic fibrosis have been diagnosed on the basis of advances in genotyping of *CFTR* mutations, which contributes to, but does not fully account for, the increase in survival. In patients 40 years and older who were diagnosed after the age of 15 years, the median age of diagnosis has been reported to be 48.8 years (range 24 to 72.8 years)²⁰; these individuals are much more likely to have a nonclassic phenotype (see below)^{21, 22}. Survival even in patients with severe lung disease (defined as a forced expired volume in 1 second (FEV₁) <30% of predicted) is improving²³, with median survival in those not receiving lung transplants increasing from 1.2 years to 5.3 years in the period of 1991–2002.

Key questions in cystic fibrosis epidemiology remain unanswered. The first question relates to the exact impact of the almost universal use of newborn screening; newborn screening could enable children to maintain their lung health into adulthood. The next key question is how the advent of *CFTR*-directed therapies such as ivacaftor^{24, 25} will change the long-term morbidity and mortality. In the future, incidence might continue to fall in part because of prenatal counselling and because of mixing of populations with differing incidence of *CFTR* mutations. However, prevalence could continue to increase as a consequence of the initiation of new therapies prior to end-organ injury.

Mechanisms/pathophysiology

CFTR protein and genetic mutations

Cystic fibrosis is caused by gene mutations of the *CFTR* gene on the long arm of chromosome 7 (Refs^{5, 26}). This gene is a unique member of the ATP binding cassette (*ABC*) or traffic ATPase family of genes^{27, 28}, which carries a regulatory domain that is actively phosphorylated^{29, 30}. *CFTR* functions primarily as an apical anion channel of chloride and bicarbonate, rather than an active pump. Like other members of the *ABC* protein family, it

houses two nucleotide-binding domains (NBDs) encoding sites capable of binding and hydrolysing ATP (Walker A and B motifs) and membrane spanning domains that serve as the ion channel pore through the plasma membrane (Figure 2).

CFTR mutations can reduce channel number, function, or both, and can vary in severity and occur through a variety of cellular mechanisms. The relative severity and completeness of each genetic defect has a major impact on the manifestations and severity of disease (that is, the cystic fibrosis phenotype), although genetic modifiers and environmental factors also have a role (<http://www.cftr2.org>)^{8, 31}. The presence of at least one *CFTR* allele that is partially active can vastly improve clinical outcome; this is also evident by lower concentrations of sweat chloride concentrations or higher likelihood of pancreatic sufficiency compared with those that have no functional *CFTR*. When two mild or ‘variable’ mutations are present, or one mutation exhibits sufficient function, atypical forms of cystic fibrosis can occur, such as congenital absence of the vas deferens³², ‘idiopathic’ pancreatitis^{33, 34}, or very late onset respiratory disease without other characteristic features of cystic fibrosis^{32–34}. A global catalogue of the phenotypes found in reported patients is available online (<http://www.cftr2.org>)³⁵, and can provide diagnostic and prognostic guidance to the management of individual patients.

The classification of *CFTR* alleles into molecular classes helps simplify our understanding of the cellular defect (Table 1); however, it is now clear that many *CFTR* mutations exhibit more than one feature³⁶. This has led to a multi-national effort to standardize the characterization of the mutations, particularly with regards to their response to therapeutics (that is, the ‘theratype’), and publicize the information through open data repositories^{35, 37}. The function of the *CFTR* protein can be reduced by disordered regulation and gating, causing diminished ATP binding and hydrolysis (Class III) or defective chloride conductance (Class IV). Reduced channel number can be conferred by major disruptions of the *CFTR* gene (insertions, deletions, and premature termination codons; each representative of a Class I allele), aberrant splicing that reduces or eliminates full-length and stable mRNA transcripts (non-canonical and canonical splicing mutations, respectively; Class V alleles), mutations that reduce surface stability (Class VI), or misfolding mutations that destabilize the *CFTR* protein and subject it to premature degradation by endoplasmic reticulum-associated degradation, disrupting its normal localization to the plasma membrane (Class II). Class II mutations include the most common *CFTR* allele, deletion of the phenylalanine at position 508 (known as F508del or c.1521_1523delCTT).

The severity of disease depends on whether a molecular defect is complete, in addition to other factors unrelated to the *CFTR* protein itself, such as modifier genes or environment. Mutations that affect chloride conductance are frequently only mild in severity; similarly, some Class II and Class VI alleles only partially disrupt protein stability, and noncanonical splice mutations are, by definition, partial owing to the presence of normally spliced transcripts. Some alleles also exhibit more than one abnormality, adding further complexity. Although the main defect that results from F508del is destabilized protein folding by altering NBD1 stability, subjecting the protein to degradation in the proteasome, the protein also alters *CFTR* gating and cell surface residence time³⁸. Indeed, F508del is at a key position within NBD1 such that it causes destabilization; furthermore, the deletion affects

interdomain assembly and the communication of conformational changes to the transmembrane domains that are necessary for channel activation^{39, 40}.

In addition to *CFTR* mutations, disease manifestations and progression are influenced by non-*CFTR* gene modifiers and environmental factors^{31, 41–44}. For example, multiple genes, which encode apical plasma membrane proteins found near *CFTR*, lead to an increased risk of meconium ileus (a condition whereby the bowel is obstructed by viscous secretions) in the newborn^{43, 45, 46}. The meconium ileus risk alleles in the genes *SLC26A9* (which mediates processes near *CFTR*), *SLC9A3* and *SLC6A14* are pleiotropic and influence other cystic fibrosis comorbidities in early life, including earlier development of lung damage and acquisition of *Pseudomonas aeruginosa* infection at a younger age⁴⁷. A large and ongoing genome-wide association study and linkage study of 3,600 patients with cystic fibrosis reported a strong association between lung disease severity and loci on chromosome 11 and chromosome 20 (Ref⁴⁸).

In several analyses from an international twin and sibling study, genetic modifiers independent of *CFTR* are estimated to account for up to 50% of the variation in lung function in patients with cystic fibrosis, with the remainder attributed to environmental exposures and stochastic effects^{49, 50}. Genetic variations in innate immune molecules (for example, mannose binding lectin 2, chloride channel accessory-4)⁵¹ and cytokines (for example, transforming growth factor β 1 (TGF β 1) and tumour necrosis factor (TNF) have been examined in many studies for their influence on clinical phenotype^{42, 52, 53}. The results have not been consistent in all populations studied, which likely reflect differences in the populations studied (in terms of population size and the distribution of *CFTR* mutation status). These studies have identified potential modifiers that can be further assessed in the large cohorts that have been established for genome-wide association studies. For example, the risk for the development of cystic-fibrosis-related diabetes has recently been shown to be influenced by modifier genes that include variants at *SLC26A9* and at four susceptibility loci for type 2 diabetes mellitus⁴⁴.

Environmental factors that have been shown to influence disease progression include exposure to environmental factors or toxins (for example, second-hand smoke, pollutants, climate and exposure to microorganisms), access to specialized care, adherence to treatment and variation in clinical practice^{54–57}. Importantly, tissue-specific differences are evident in the susceptibility to *CFTR* mutations, non-*CFTR* gene modifiers and environmental factors. For example, specific *CFTR* gene mutations strongly affect pancreatic function (phenotype)⁵⁸, but environmental and other nongenetic factors have a greater influence on the pulmonary phenotype. The combination of large cohorts with the reduced costs and enhanced processing of vast genetic data in the coming years are likely to provide understanding of the complex relationships between *CFTR*, non-*CFTR* gene modifiers and environmental factors on disease manifestations in cystic fibrosis.

Airway pathophysiology

Cystic fibrosis affects the function of epithelial tissues in which *CFTR* is highly expressed, in particular glandular epithelia. The disease primarily manifests in the lung, pancreas, gastrointestinal tract, vas deferens, and sweat gland, although airway disease is the main

cause of morbidity and mortality. In the lungs, cystic fibrosis results in mucus accumulation that compromises the airway lumen, and contributes to obstructive pulmonary disease (Figure 3). Submucosal gland hyperplasia and thickened mucus secretions are also prominent. Airway disease is thought to begin in the small airways⁷. Development of bronchiectasis leads to irreversible changes that encourage continued infection and accelerate disease pathogenesis.

Despite decades of research, the understanding of the origins of airway pathogenesis remains incomplete and continues to evolve. Several key manifestations include delayed mucociliary clearance through airway surface liquid depletion, abnormalities of the physical properties and adhesion of mucus, and a predisposition to infection owing to abnormal mucosal defences^{59, 60}. Dysregulated inflammation intrinsic to the CFTR defect is also apparent. These processes initiate and perpetuate a cycle of destruction that ultimately results in irreversible lung injury, bronchiectasis and respiratory failure^{59, 60}.

Loss of apical CFTR leads to reduced chloride and bicarbonate secretion⁶¹. Given that the release of water and electrolytes onto the airway surface is driven in large measure by CFTR-dependent fluid secretion through both the glands and the surface epithelia, CFTR deficiency leads to diminished airway surface hydration, which can impair mucociliary transport in itself⁶¹. CFTR has also been shown to regulate the activity of the epithelial sodium channel (ENaC; also known as the amiloride-sensitive sodium channel), which is also activated by cleavage events conferred by free proteases such as prostatic and neutrophil elastase, which are enriched in the inflamed airway^{62–64}. CFTR decrement also confers unopposed ENaC-dependent sodium and water absorption, which exacerbates airway surface liquid depletion⁶⁵. Moreover, the periciliary layer, a mucin gel layer between the cell surface and the mucus layer (Figure 3), is sensitive to the osmolar forces of the overlying mucus; as the overlying mucins become concentrated in the absence of adequate fluid transport, the periciliary layer collapses and failure of mucociliary transport ensues⁶⁶. However, this view is not without controversy. Specifically, ENaC hyperactivity has been questioned owing to the absence of sodium hyperabsorption from airway mucosa in newborn pigs with cystic fibrosis (together with evidence of normal airway surface liquid depth)⁶⁷, the lack of heightened amiloride-sensitive currents in rat models⁶⁸, and the demonstration that elevated amiloride-sensitive currents can be increased by reduced CFTR-dependent transepithelial resistance in primary human airway epithelial monolayers derived from patients with cystic fibrosis⁶⁹. Even in the presence of adequate airway hydration, mucus abnormalities can adversely affect mucociliary transport⁷⁰, and mucus adhesion can occur at the gland outlet even under submerged conditions, suggesting multifactorial causes to delayed mucociliary clearance⁷¹.

Mucus and glandular epithelium abnormalities

Hyperviscous respiratory secretions obstruct small and medium airways, leading to profound failure of mucociliary clearance that can be verified macroscopically by radioligand imaging⁷². A primary biochemical defect in mucus composition has been explored but is not well established as a fundamental cause of the disease, although enzymatically driven events that lead to the release of intestinal mucins have been identified⁷³. Mucus includes a

complex array of extracellular proteins, which are found in high concentration in the airway lumen⁷⁴.

In extrapulmonary organs (for example, the pancreas and liver), profound ductular obstruction is observed in the absence of polymicrobial infection, enabling direct studies of the relationship between CFTR and mucus formation. An emerging notion implicates defective bicarbonate transport as a mediator of hyperviscosity and mucosal adhesion in cystic fibrosis⁷⁵. In this model, exocrine mucus — which is highly negative in charge — is produced by acinar and other epithelial cells. This mucus binds calcium ions, which condenses the mucus and shields the negative repulsive force between sulfates and other anionic groups on constituent mucins⁷⁵. Bicarbonate secretion via CFTR chelates calcium, and permits mucinous expansion and a viscoelastic state compatible with physiologic clearance. Failure of bicarbonate release is hypothesized to result in defective mucin expansion, leading to hyperviscous secretion with abnormally adherent properties; that is, the mucus is tightly bound to the epithelial surface and is difficult to mobilize. Evidence of excessive mucus viscosity and adhesion that depends on bicarbonate secretion has been observed in the intestine of mouse models of cystic fibrosis^{76, 77} and excised airways of model pigs⁷⁰. Notably, CFTR is highly expressed in the glandular epithelium, where it activates fluid and electrolyte secretion^{69, 71}; CFTR-dependent anion transport is also crucial for the release of elastic mucus from the gland duct, even under submerged (hydrated) conditions, indicating its importance to normal mucus maturation and transport⁷¹. As only large-animal models of cystic fibrosis (for example, pig, ferret and to a lesser extent rat) have prominent gland expression, this might explain why mouse models are minimally affected by lung disease^{68, 78, 79}.

Defects in airway defence

Although CFTR mainly functions as an anion transporter, it also regulates numerous processes, including fundamental aspects of airway defence and inflammatory cell function. CFTR is situated within membrane complexes in close proximity to a number of integral membrane proteins, including other ion channels. In addition to ENaC, CFTR can directly or indirectly regulate anion secretion through other chloride channels, such as transmembrane member 16a (TMEM16a; also known as anoctamin-1), or contribute to airway pH regulation through chloride exchangers, including anion exchanger type 2^{80, 81}. The absence of bicarbonate secretion leads to an acidic pH airway surface liquid in cystic fibrosis, which has been reported as a possible cause of defective bacterial killing by the highly pH-sensitive innate defensins⁸². CFTR also has a direct effect on neutrophil killing, as it affects degranulation by interfering with granule trafficking⁸³. Dysfunctional macrophages might also be biased towards a proinflammatory response⁸⁴. Proteomic and transcriptome analyses demonstrate hundreds of cellular gene products that directly bind to or are regulated by CFTR. Accordingly, additional effects of CFTR are likely to emerge, in part fostered by studies using agents that specifically activate the protein⁸⁵.

Inflammation in lung disease.—Whether infection is required to cause airway inflammation in cystic fibrosis remains under debate. Post-mortem studies have reported that babies with cystic fibrosis who died from meconium ileus had normal (or near to normal)

airway epithelium and no signs of inflammation or infection⁸⁶. However, animal models have suggested that abnormalities of mucus can be proinflammatory in the absence of infection⁸⁷ and endoplasmatic reticulum-associated protein degradation induced by misprocessed F508del *CFTR* might also provide a stimulus for a heightened inflammatory response⁸⁸. Despite this controversy, what is clear is that infection exaggerates the inflammatory milieu. Excessive, neutrophil-dominated inflammation is observed in the absence of infection⁸⁹ and neutrophil elastase activity (a marker of airway inflammation) in bronchoalveolar lavage fluid in infants (3 months of age) was associated with early bronchiectasis at 12 months and 3 years of age in children with cystic fibrosis⁹⁰.

Factors released in chronic neutrophilic inflammation in cystic fibrosis can profoundly reduce airway surface liquid height⁹¹. As well as aggravating airway dehydration, the imbalance between neutrophil elastase, other proteolytic enzymes (derived from inflammatory cells or bacteria) and anti-proteases results in exaggerated tissue damage^{92, 93}. Oxidative stress and persisting airway inflammation might be associated with local airway deficiency in glutathione (which normally protects from reactive oxygen species)^{94, 95}. Over time, a vicious cycle of reduced mucus clearance, neutrophil-dominated inflammation and bacterial infection damages the airway⁹⁶.

Lung infection.—Airway pathogens that are most commonly detected include *P. aeruginosa*, *Staphylococcus aureus*, and *Aspergillus* species. *P. aeruginosa* infection has been associated with increased mortality, frequent exacerbations, rapid decline in lung function and heightened inflammation in patients with cystic fibrosis, which has fuelled programmes of eradication over the past two decades^{97–99}. Viral infection is also a common cause of exacerbations in people with cystic fibrosis^{100, 101} — although these patients are not more susceptible to viral infection, the impact is greater¹⁰². Fungi including *Aspergillus* species are also increasingly recognized as pathogens in cystic fibrosis and are associated with an increased rate of pulmonary exacerbations¹⁰³.

With increasing age, infections with other bacteria —including *Achromobacter xylosoxidans*, *Stenotrophomonas maltophilia* and *Burkholderia cepacia* complex — become increasingly common¹⁶. The prevalence of each of these pathogens varies between cystic fibrosis populations although they generally occur in <15% of patients and rates increase with disease severity. Methicillin-resistant *S. aureus* (MRSA) is an increasing threat that occurs in up to 30% of patients presenting at some US centres^{16, 104}, though the rates are lower in Europe. In the late 1980s, epidemic strains of *B. cenocepacia* were associated with clear evidence of cross-infection, rapid clinical deterioration in many and poor outcomes following lung transplantation¹⁰⁵. Both MRSA and *B. cenocepacia* infection in patients with cystic fibrosis have been reported to have adverse effects on prognosis^{104, 106}. Although *P. aeruginosa* was previously thought to be acquired from the environment, sharing of strains (patients with the same strains) has been shown to be common over the past 15 years, with some strains being associated with adverse clinical outcomes^{107–109}. In some settings, strong evidence supports person-to-person spread of shared strains, although in other clinical settings common strains in patients with cystic fibrosis are genetically indistinguishable from common environmental strains^{107, 109–111}. Prevention of cross-infection has become a key part of the management of all patients and implementation of intensive infection control

measures has reduced rates of shared strain infection in treatment centres^{112, 113}. However, such control measures remain challenging in resource-limited settings, especially with the rapid growth in the numbers of adults with cystic fibrosis.

Non-tuberculous mycobacteria cause infection in 3–20% of patients with cystic fibrosis¹¹⁴ and prevalence rates have increased over the past 10 years¹¹⁵. Rapidly growing species (for example, *Mycobacteria abscessus*) are difficult to treat because prolonged courses of multiple antibiotics are required, which are often associated with toxicity and are a contraindication for lung transplantation in many transplant centres⁶⁶. Of recent concern are the reports suggesting the potential for person-to-person transmission of *M. abscessus*¹¹⁶.

Over the past several years the airway has been revealed as not sterile in health and the airway in cystic fibrosis is now considered to harbour a polymicrobial milieu. Both non-culture-based and culture-based methods have demonstrated a wide range of atypical bacterial species, including *Prevotella*, *Fusobacterium*, and *Veillonella spp.* amongst others^{117, 118}. The clinical significance of the microbiome on disease progression remains to be established, but several features are emerging — including a heterogeneous microbiome composition in patient populations and lower bacterial diversity with increasing age and poorer lung function¹¹⁹.

The lung in cystic fibrosis is a microaerophilic environment and *P. aeruginosa* survives and in fact thrives within low oxygen tension biofilms¹²⁰. Chronic *P. aeruginosa* infection is also associated with ongoing microevolution, which alters virulence, regulatory networks and acquisition of antimicrobial-resistance mechanisms^{121, 122}. These factors likely contribute to the persistence of *P. aeruginosa*. The interaction of the host with pathogens is crucial for the development and progression of pulmonary disease in cystic fibrosis, leading to perpetual neutrophil recruitment to the lung (the dominant inflammatory cell)¹²². A key component of this dysregulation is the development of neutrophil extracellular traps (NETs), which are stimulated by bacterial pathogens (such as *P. aeruginosa* and *S. aureus*)¹²³. NETs have detrimental effects in the cystic fibrosis airway by enhancing the viscosity of airway secretions, dampening pathogen clearance and potentially enhancing biofilm development and persistence¹²³. The macrophage is likely to be an important scavenger in the lung in patients with cystic fibrosis, but the mechanisms of action are debated. Some studies have suggested that T lymphocytes accumulate within the subepithelial airway but are limited in the lumen¹²⁴. Whether specific lymphocyte subsets have an important role in lung disease remains controversial. Evidence would suggest that T helper 17 (T_H17) cells are important drivers of neutrophilic inflammation and an abnormal regulatory T-cell response has been described to be linked to CFTR deficiency^{125, 126}. The impact of polymicrobial infection is likely to add to the complexity of regulation of immune responses in the cystic fibrosis airway.

Diagnosis, screening and prevention

Principles of diagnosis

The conventional diagnostic criteria for CF are given in Box 2. Increasingly, diagnosis is by newborn screening (see below). However, physicians should be aware of symptoms and

signs of disease in older children and adults, in particular, bronchiectasis, recurrent respiratory tract infection, nasal polyps, male infertility and portal hypertension; late presenting patients are usually — but not invariably — pancreatic sufficient. Screening can miss some mild cases if the child is born in a region without routine screening, the child missed screening despite being born in a screening region or a laboratory error occurred.

More than 95% of patients presenting symptomatically can be diagnosed with a sweat test. The test measures chloride concentration after pilocarpine (a muscarinic receptor agonist) application, which stimulates sweat production, but in a small minority of patients the diagnosis is unclear even after extensive testing¹²⁷. The upper limit of normal sweat chloride concentration remains under contention; in Europe the upper limit of normal for an indeterminate result is 30 mmol/l regardless of age. Given that sweat chloride concentration can increase with age, 40 mmol/l is considered the upper limit after 6 months of age only in the United States. Above 60 mmol/l is definitely abnormal and, provided the clinical presentation is compatible, is diagnostic¹²⁸. However, rare but unequivocal cases of cystic fibrosis have been reported with sweat chloride <30 mmol/l, which likely resulted owing to heterogeneity in end-organ CFTR expression or the influence of other related genes such as that encoding ENaC¹²⁹.

Genetic testing is an important part of diagnostics, because mutation-specific therapy is an increasing reality, and can also help to resolve unclear cases. Given the marked variation in the prevalence of *CFTR* mutations between different ethnic groups, test panels that account for this variation should be used unless whole-exome sequencing is performed. Additionally, the unknown significance of most of the rare *CFTR* mutations does not support the use of extended genotyping in patients with equivocal diagnostic tests¹²⁷.

Measurement of transepithelial potential difference is an adjunct diagnostic test, but is only available in only a few specialist centres. The *in vivo* technique usually measures the potential difference across the nose or respiratory epithelium via a catheter referenced to a peripheral electrode^{130–132}. Rectal potential difference can also be measured *in vivo*; alternatively, *in vitro* measurement of CFTR activity on excised rectal biopsy tissue can be performed via open-circuit or closed-circuit currents^{133, 134}. Other *in vitro* methods for assessing CFTR function, such as intestinal organoid swelling or the function of nasal epithelial cells grown in culture, are also of emerging interest¹³⁵. The nasal potential difference test in patients with cystic fibrosis has several cardinal features, including elevated potential difference at baseline, a heightened response to amiloride, and a diminished response to chloride-free isoproterenol compared with healthy controls (Figure 4). A modified sweat test that assesses β -adrenergic sweat secretion has recently been developed and might have advantages in individuals with mild disease. However, its diagnostic utility is not yet well established¹³⁶. Other supportive tests can be considered to clarify the diagnosis, including stool human faecal elastase measurement for pancreatic insufficiency and, in postpubertal men, semen analysis to test for azoospermia³².

Diagnosis is hindered in patients with positive diagnostic tests but without symptoms, and patients with a cystic fibrosis phenotype but negative or equivocal diagnostic tests¹³⁷. The latter case is relatively straightforward; irrespective of the underlying diagnosis, any organ

disease should be treated on its merits and the patient carefully monitored. Seemingly symptom-free patients with positive diagnostic tests should be followed carefully to detect the development of complications¹³⁸, whilst not overburdening the patients with treatment.

Newborn screening

Newborn screening for cystic fibrosis has been controversial because of its cost, the creation of anxiety around the procedure in seemingly healthy infants, and the lack of established pulmonary treatments for infants. The cost of treatment has been shown to be reduced in patients who have been diagnosed through newborn screening as compared with later diagnoses¹³⁹. A randomized controlled trial has clearly demonstrated the efficacy of screening and provided evidence of nutritional — but not respiratory — benefits¹⁴⁰. However, a factor in the unexpectedly poor respiratory outcomes in that study might have been failure to apply modern infection control precautions in one of the participating centres. Much evidence shows benefit when comparing outcomes before and after the introduction of screening^{141–143}. For example, The London Cystic Fibrosis Collaboration showed that infants diagnosed later (in the first 2 years of life) had airway obstruction at presentation, even if they had had no respiratory symptoms or signs, and this never recovered despite specialist treatment^{144, 145}. By comparison, the outcomes in babies diagnosed by screening were much more favourable (see below). Another benefit of newborn screening is that parents have the opportunity to make informed choices about antenatal diagnosis in future pregnancies.

A large number of screening protocols are available, including measurements of serum immunoreactive trypsin (iRT) and *CFTR* mutation analysis^{146–148}. Screening diagnosis must always be confirmed with a sweat test, not least to ensure that there has been no error in the screening laboratory. The possible outcomes are: a definite diagnosis of classic cystic fibrosis depending on the protocol, cystic fibrosis definitely excluded, or an indeterminate outcome. Indeterminate outcomes are the most challenging situations; these children fall into two groups, namely those harbouring *CFTR* mutations who will develop late onset, mild-variant disease and those with true diagnostic uncertainty¹⁴⁹. Thus, screening can lead to the child being given a diagnosis of cystic fibrosis that might not have been possible until middle age. Such a situation raises the question of whether an early diagnosis impacts the quality of life of the individual and their family. If accurate information is carefully given, and the intensity of treatment and monitoring is appropriately applied according to the severity of the clinical state, quality of life need not be negatively affected. However, there is disagreement even between experts about some variants (for example, R117H with the 7T intron 8 variant in *trans*), with some believing this is a benign variant whereas others have identified late-presenting patients with this mutation^{150–153}.

True diagnostic uncertainty is another outcome of screening. The US Cystic Fibrosis Foundation has coined the phrase ‘*CFTR*-related metabolic syndrome’ to describe infants with sweat chloride values <60 mmol/l (which could be too high an upper limit of normal in infancy, given that virtually all healthy babies have a sweat chloride <30 mmol/l) and two *CFTR* mutations, one of which has not been shown to be disease-causing¹⁵⁴. An alternative term — cystic fibrosis screen positive with inconclusive diagnosis (CFSPID) —

has been proposed by the European Cystic Fibrosis Working Group¹⁵⁵. However, some of these infants develop cystic fibrosis-like symptoms, and current recommendations are for careful follow-up monitoring¹⁵⁶. Nonetheless, despite these issues, the case in favour of newborn screening is overwhelming.

Detection of early lung disease

Infants who are diagnosed through screening are often asymptomatic with few if any clinical signs of lung disease. When investigating these infants, it is important not to miss significant warning signs or to cause anxiety by over-interpreting trivial abnormalities. Current techniques to identify lung disease are lung function measurements, imaging (mainly high-resolution CT and bronchoscopy, although MRI is being used increasingly¹⁵⁷) and bronchoalveolar lavage.

In terms of lung function tests, spirometry measures lung volume and air flow but is insensitive to distal airway disease. In preschool and school-age children, multi-breath washout (the lung clearance index; LCI) is the most sensitive test in clinical practice and outperforms spirometry and lung volume assessment by bodyplethysmography^{158–160}. However, in the first 2 years of life, LCI will fail to detect a substantial number of children who have abnormal infant spirometry, so the two tests should be combined in this age group¹⁶¹. Two large collaborative projects have evaluated lung function in infants with differing results: although both groups reported that lung function was abnormal at diagnosis^{162, 163}, the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF) reported rapid and profound deterioration¹⁶⁴, whereas the London CF Collaboration (LCFC) showed improvement over the first year of life, with stabilization in the second year^{165, 166}. These differences could be explained by differences in treatment strategies or in the characteristics of the population studied.

LCI has also been used as a clinical trial end point; one study has shown an elevation in LCI predicts pulmonary exacerbations^{167–169}. The role of high-resolution CT is controversial owing to the radiation exposure and potentially increased baseline risk of some epithelial cancers in patients with cystic fibrosis¹⁷⁰. Indeed, its role in infants diagnosed through screening is debated; the AREST-CF group has shown a large number of lung abnormalities⁹⁰, whereas the LCFC group found that CT changes at 1 year of age were so mild that they could not be scored reproducibly, and accordingly abandoned the technique¹⁷¹. In school-age children, if LCI is abnormal, then the CT will also very likely be abnormal, and the number of scans could, therefore, be reduced^{172, 173}. If high-resolution CT is performed, dilated airways should not be assumed to be ‘bronchiectatic’ (that is, irreversibly dilated) as air trapping might simply reflect transient mucus plugging rather than any structural disease. No study has shown that regular CT scans improve prognosis, and scanning should be reserved for selected cases.

Identification of lower respiratory tract pathogens can be hampered by the patients’ inability to spontaneously produce a sputum sample; for these patients, bronchoalveolar lavage can be considered. Early bronchoalveolar lavage surveillance programmes have shown that infection and inflammation in the absence of symptoms is common^{89, 99, 174}. A 5-year, prospective randomized controlled trial showed no benefit from an aggressive programme of

regular bronchoscopies; this technique should only be reserved for children who are symptomatic despite antibiotic treatment¹⁷⁵. Early elevation of bronchoalveolar lavage neutrophil elastase activity has been shown to predict later structural changes on CT⁹⁰, but no evidence currently supports that detecting neutrophil elastase facilitates an intervention that improves prognosis.

Extrapulmonary manifestations

Cystic fibrosis is a multi-system disease that affects many organs in which *CFTR* is expressed. Chronic rhinosinusitis is extremely common and nasal polyposis a complication in up to 45% of patients^{176, 177}. Persistent infection in the upper airways and sinuses can be a source of lower respiratory tract infection¹⁷⁸. The gastrointestinal tract is affected in numerous ways, including increased nutrient loss secondary to pancreatic insufficiency, reduced fat-soluble vitamin absorption, fat-soluble vitamin deficiency states, frequent gastro-esophageal reflux, impaired bowel transit (complicated by distal intestinal obstruction syndrome, constipation, and small intestinal bacterial overgrowth)^{179–183}. The early recognition of nutritional deficits is vital, as poor growth and malnutrition adversely affect pulmonary function and patient survival^{184, 185}. Hepatic involvement is also common, with up to one in three patients affected including those with evidence of hepatic steatosis, cholelithiasis, ductal stenosis and focal biliary cirrhosis^{186, 187}. Biliary cirrhosis usually becomes clinically evident in late childhood or early adolescence and leads to portal hypertension.

Cystic-fibrosis-related diabetes is increasingly common with advancing age and represents a clinically distinct form from type 1 and type 2 diabetes mellitus in the general population¹⁸⁸. Importantly, its occurrence adversely affects survival in patients with cystic fibrosis¹⁸⁹. Other endocrinological complications of cystic fibrosis include delayed menarche in malnourished adolescent females and reduced bone mineral density, which can increase the risk of bone fractures and is multifactorial¹⁹⁰. Congenital bilateral absence of the vas deferens occurs in 98% of males with cystic fibrosis and results in azoospermia; intracytoplasmic sperm injection or related procedures are required for these men to father children. Renal complications can occur and include nephrocalcinosis and salt and water depletion owing to excess fluid losses, which contribute to acute kidney injury and proteinuria. These renal complications can occur even in those without evidence of diabetes. Chronic kidney disease is more common in adult patients and risk factors for its development include age, diabetes, prior episodes of acute kidney injury and prior organ transplantation. As survival for patients with cystic fibrosis has increased, a number of complications have been recognized and these include an increased risk of colorectal and other gastrointestinal malignancies, the potential for macrovascular disease to complicate longstanding inflammatory disease and venous insufficiency.

Management

Clinical outcomes in cystic fibrosis vary between countries and centres^{57, 191–194} and evidence for many areas of clinical decision making is lacking. Thus, the current focus is on benchmarking projects⁵⁷, the establishment of standards of care and management

guidelines^{195, 196} and the development of multidisciplinary specialist care programmes that operate in collaboration with the patient and their family¹⁹⁷. National (US) and international data registries of patients with cystic fibrosis were established in the 1960s^{18, 198, 199}. These registries are central for clinical research and care^{19, 56, 200–202}. Public reporting of data and benchmarking between centres have led to improvements of clinical outcomes in less well achieving centres and high-achieving centres^{57, 203}.

Over the past 20 years, therapies and the time and effort required by patients and their families have increased dramatically. Not surprisingly, adherence to prescribed therapies is quite low²⁰⁴, with lowest rates of adherence observed for airway clearance and nebulized medications. One US study indicated that, overall, adherence to pulmonary therapies is 50%, with decreases in adherence related to increasing age from childhood through adulthood^{205, 206}. Similarly, use of complex and life-long therapies has led to the emergence of treatment-related toxicities, β -lactam allergies, aminoglycoside nephrotoxicity and vascular complications from long-term intravenous access devices²⁰⁷.

Early recognition and treatment of lung disease²⁰⁸ and exacerbations^{209, 210}, *P. aeruginosa* eradication and prevention of chronic infection, optimizing nutritional status, adequate mobilization of airway secretions and physical fitness and the psychosocial management require regular consideration²¹⁰. Indeed, with the adult cystic fibrosis population growing rapidly, comprehensive transitional care programmes should be available at all centres with regular communication between paediatric and adult teams^{210, 211}. The key components of pulmonary care of all people with cystic fibrosis are knowledge, participation and monitoring of airway clearance and the appropriate use of maintenance therapies such as mucolytic therapy, hydrators, and antibiotics (Figure 5).

Pulmonary disease

Airway clearance and exercise.—Daily airway clearance is considered a standard of care, although the strength of evidence to support long-term benefit is limited²¹². Modes of airway clearance include percussion, device assistance (for example, positive expiratory pressure and vest and handheld vibratory devices) and breathing modalities (for example, autogenic drainage). Although few comparative trials have been performed, one has shown positive expiratory pressure to be associated with a lower rate of pulmonary exacerbations — an outcome measure that is associated with lung function decline — than an oscillating vest device²¹³. Aerobic exercise results in improved exercise tolerance and increased physical activity has been linked to reduced lung function decline^{214, 215}.

Mucolytic and hydrator therapies.—Dornase alfa, a recombinant human DNase, breaks down DNA derived from degrading neutrophils that accumulate in the airways of patients with cystic fibrosis, thereby reducing viscosity of airway secretions leading to improved lung function and reduced exacerbations^{216, 217}. The first large scale study to show benefit of nebulized dornase alfa was reported >20 years ago²¹⁶. Subsequently, benefits have been demonstrated in patients with advanced lung disease (FEV₁ predicted <40%) and in younger patients with mild disease^{218, 219}. This therapy is considered standard of care in patients >5 years of age^{210, 220}.

Hypertonic saline acts as a hydrating agent that increases mucociliary clearance and has been demonstrated to improve lung function and reduce exacerbations in a randomized controlled trial²²¹. A reduction in exacerbations was not observed in a study of children age 4 months to 5 years, but substudies have demonstrated positive effects on lung function^{222, 223}. Additional studies to assess the efficacy of hypertonic saline in younger children are currently ongoing. Inhaled dry-powder mannitol is another osmotic agent that has showed lung function improvements in two trials; effects have been more consistent in adults than in children^{224, 225}.

Inhaled antibiotics.—In patients with chronic *P. aeruginosa* infection, nebulized tobramycin (an aminoglycoside antibiotic) improved lung function, reduced exacerbations and increased weight^{226, 227}. More recently, a dry-powder preparation of tobramycin that decreases delivery time has been shown to have equal efficacy and better patient satisfaction²²⁸. Inhaled aztreonam (a β -lactam antibiotic) has also been shown to be efficacious both when compared to placebo and to inhaled tobramycin^{229, 230}. Other antibiotics such as colistin are used in some countries and several new preparations of inhaled antibiotics are currently being studied²³¹. To date, few studies have examined the role of inhaled antibiotics for other bacterial infections common in patients with cystic fibrosis (*B. cepacia* complex, MRSA, *A. xyloxidans*)²³².

Macrolides.—Several randomized controlled trials have demonstrated improved lung function, quality of life, weight and reduced time to next exacerbations in *P. aeruginosa* infected patients treated with azithromycin^{233, 234}. The mechanism of action of macrolides in cystic fibrosis might be anti-inflammatory rather than antibacterial. In patients without *P. aeruginosa*, when treated with azithromycin, lung function improvement was not observed but there is evidence of a reduced pulmonary exacerbation rate^{235, 236}. An increasing prevalence of nontuberculous mycobacteria in a single-centre study has raised concerns whether long-term azithromycin treatment is a contributory factor. This finding was not supported by a subsequent national data registry analysis^{114, 116}, but the impact of macrolides on non-tuberculous mycobacterial infection remains controversial as complete case ascertainment is unlikely in registry analysis.

Anti-inflammatory therapies.—Several anti-inflammatory therapies have been studied in patients with cystic fibrosis, including oral corticosteroids, inhaled corticosteroids, non-steroidal anti-inflammatory drugs (such as ibuprofen) and leukotriene inhibitors. Although ibuprofen reduced the rate of decline in lung function, especially in younger patients and adolescents, its uptake has been limited due to the need to monitor blood levels to optimize benefit^{237, 238}. Oral steroids are associated with adverse side effects and inhaled steroids have limited effect in patients who do not have asthma in addition to cystic fibrosis^{239–242}. A leukotriene B4 inhibitor (known as BIIL 284) was associated with increased exacerbations and led to an early termination of one trial, raising concerns that anti-inflammatory therapies involve a delicate balance between reducing inflammation without adversely affecting the patient's response to infection²⁴³.

Lung transplantation.—Lung transplantation is the established treatment for patients with end-stage pulmonary disease. The outcomes for patients undergoing transplantation for cystic fibrosis have improved rapidly and median survival now approaches or even exceeds 10 years in many treatment centres. Timely referral and close communication between the cystic fibrosis and transplant centres is required to provide sufficient time for assessment of suitability (of the donor and recipient), to determine if indications are met and to establish that there are no foreseeable contraindications. Donor allocation programmes vary globally, but aim to prioritize those waiting for transplant with the most limited pre-transplant survival²⁴⁴. Adjunctive therapies including noninvasive ventilation can act as a bridge to transplantation²⁴⁵. The most common cause of graft failure following lung transplantation is bronchiolitis obliterans, which is thought to be a form of chronic allograft rejection²⁴⁴.

Extrapulmonary disease

As median survival from cystic fibrosis has approached or even exceeded 40 years, complications have emerged. For example, gastrointestinal malignancy, hyperlipidaemia, metabolic and endocrine complications and multi-resistant infections have emerged and are providing new challenges²⁰⁷. Involvement of an interdisciplinary team and access to specialist support, including experts in microbiology, general surgery, thoracic surgery, gastroenterology and hepatology, otolaryngology, obstetrics and gynaecology, clinical genetics, endocrinology, palliative care and transplantation services are increasingly important for the adult with cystic fibrosis²¹⁰.

Treatment of the basic defect

In terms of treating the basic genetic defect, therapies targeting CFTR dysfunction operate by inserting a normal copy of *CFTR* into patients cells (gene therapy), improving the expression of CFTR on the cell surface, increasing the ‘opening probability’ of existing channels (CFTR pharmacotherapy) or by targeting other ion channels to compensate for its dysfunction.

Gene therapy.—Somatic gene therapy has been largely studied as topical therapy administered to the airways to minimize systemic toxicity. The technique enables transient expression of mature and functional CFTR on the cell surface, as shown in cell cultures and in mice²⁴⁶. Human trials initially focused on adenoviral vectors owing to its high transfection efficiency *in vitro*. Single-dose trials involving nasal or intratracheal administration demonstrated transient expression of CFTR without substantial adverse effects at low doses^{247, 248}. However, repeated dosing is associated with an immune response that reduces transfection efficiency and clinical benefit has not yet been demonstrated²⁴⁹. Modifications of adenoviral vectors might help to reduce their immunogenic potential.

Using adeno-associated virus as the vector is less immunogenic than adenoviral vectors and initial studies have suggested prolonged expression and positive trends in clinical outcome measures²⁵⁰. However, this finding was not subsequently supported in a longer term multi-dose trial²⁵¹. Lentiviral vectors are currently being explored in preclinical studies, where they have shown high transfection efficiency and prolonged activity of CFTR expression²⁵².

Liposomal vectors could potentially overcome these limitations of viral vectors. Liposomes are less immunogenic and, therefore, better suited for repeated dosing; unfortunately this positive attribute is associated with a lower level of transfection efficiency. A multicentre multiple dose trial has recently been completed by The UK Cystic Fibrosis Gene Therapy Consortium and results are expected soon²⁵³. Delivery of RNA rather than DNA is another strategy that is currently being explored²⁵⁴.

Translational readthrough therapy.—Class I mutations include premature termination codons (PTCs) that lead to a truncated protein and mRNA transcripts that undergo nonsense mediated decay. Aminoglycosides, such as gentamicin, can bind to the ribosome and enable readthrough of PTCs, leading to some production of the full length protein and partial restoration of channel function. Both *in vitro* studies and studies using topical application to the nasal epithelium in patients carrying stop mutations on at least one allele have shown evidence of CFTR expression after gentamicin treatment²⁵⁵. Clinical applicability is limited as prolonged administration of gentamicin is required, which would likely cause renal and/or ototoxicity.

Ataluren was developed as a compound with similar translational readthrough properties but lacks the potential adverse effects of aminoglycosides²⁵⁶. Initial uncontrolled studies in patients demonstrated improvement in chloride conductance measured by nasal potential difference, but a larger placebo controlled trial failed to demonstrate clinical benefit^{19, 257}. However, the subgroup of patients not receiving inhaled antibiotics and without chronic exposure showed less lung function decline after 12 months, an effect that could be explained by competitive inhibition at the level of the ribosome. One study (NCT02107859) [CE: I requested this in the text before the change in how we cite clinical trials. The URL is <https://clinicaltrials.gov/ct2/show/NCT02107859> for when you add it to the ref list] is under way to assess efficacy in this subgroup prospectively. Overall, the benefits observed so far are limited in magnitude, but could likely be increased by combining ataluren with a CFTR potentiator.

CFTR potentiator therapy.—Mutations that exhibit residual surface expression are potentially amenable to drugs that increase channel opening probability. These drugs are called potentiators and the first drug, ivacaftor, has been approved for clinical use in patients with class III mutations in most countries. The most common *CFTR* class III mutation, G551D, is associated with normal cell surface expression, but reduced gating. Ivacaftor improves CFTR function as evidenced by improvement in ion channel measurements^{24, 25, 258}. Notably, sweat chloride concentrations fell below the diagnostic threshold in most treated patients — a result that has been confirmed in an observational study²⁵⁹. This drop in sweat chloride is accompanied by marked improvement in lung function as well as improvements in other clinical measures (weight, symptoms and pulmonary exacerbations)²⁵⁸. Similar effects have been described in other gating mutations, underlining the potential of CFTR pharmacotherapy in a broader array of *CFTR* mutations^{259, 260}.

Studies are also underway in other mutation classes that could benefit from potentiation of CFTR function, including class IV and class V mutations as well as mutations in class VI

that are associated with residual CFTR function. In addition, as readthrough and corrector therapy is unlikely to normalize CFTR function alone, potentiators might be needed for combination therapy in patients carrying class I or class II mutations. Potentiation of CFTR function could also be of benefit in diseases with secondary CFTR dysfunction, such as chronic bronchitis, as smoke exposure has been found to cause secondary CFTR dysfunction²⁶¹.

Intracellular trafficking.—The most common *CFTR* mutation, F508del, is associated with defective protein folding that results in proteasomic degradation with very little or no CFTR reaching the apical membrane (class II). Indeed, as little or no CFTR is expressed on the cell surface in F508del homozygous patients, potentiators such as ivacaftor have little effect on chloride transport in bronchial epithelial cells; this finding has recently been confirmed in a phase II study²⁶². Drugs affecting CFTR transport have been called ‘correctors’ even though they do not necessarily correct the folding defect. Some correctors alter cell chaperones and other quality control mechanisms; nevertheless, their use generally increases trafficking to the cell surface. The best studied compounds have evolved from high-throughput screening programmes, with two small molecules — lumacaftor and VX-661 — having undergone clinical studies. Given alone, both compounds have little clinical benefit in those with F508del; in fact, lung function worsened in patients on lumacaftor alone²⁶³. However, when ivacaftor was added to lumacaftor, lung function improved above baseline²⁶³. The effect magnitude was significantly less than that in response to ivacaftor alone in patients harbouring the G551D mutation (class III), corroborating results from *in vitro* experiments in human bronchial epithelial cells²⁶⁴. Recent *in vitro* data suggest that ivacaftor-mediated CFTR activation might destabilize F508del CFTR and decrease the beneficial effects of some correctors, including lumacaftor; whether this finding is relevant *in vivo* is currently unclear, but this interaction could be one explanation for the relatively modest clinical effect of combination therapy with ivacaftor and lumacaftor in F508del homozygous patients^{265, 266}. Although the clinical efficacy data of combination therapy is promising, it has become clear that the search for additional CFTR corrector compounds needs to continue. Adding a second corrector has been shown to improve the efficacy of lumacaftor and ivacaftor *in vitro*²⁶⁷ by addressing distinct cellular mechanisms.

Ion channel directed therapy.—Cystic fibrosis is associated with decreased chloride and bicarbonate secretion through CFTR and increased sodium absorption by ENaC. Another potential mechanism to address the ion dysbalance on the epithelial surface is to target other apical ion channels. Activation of the apical calcium-activated chloride channel using derivatives of its natural activator ATP has been studied using the P2Y receptor agonist denufosal. Although initial studies showed some promise, beneficial effects could not be confirmed in subsequent studies^{268, 269}. Inhibition of sodium absorption was initially approached using amiloride, but limited clinical efficacy was demonstrated²⁷⁰. More potent and specific inhibitors with a longer half-life are currently being developed.

Quality of life

There is growing recognition of the importance of patient-reported outcomes (PROs), in health outcomes research and clinical care²⁷¹. These instruments, which include health-related quality of life (HRQOL) measures, can be used for several purposes: as primary or secondary outcomes in clinical trials of new medications or behavioural interventions^{221, 272, 273}; to document the natural progression of the disease²⁷⁴; to describe the impact of an illness on patient functioning²⁷⁵; to analyse the costs and benefits of medical interventions; and to aid in communication and clinical decision-making²⁷⁶.

Quality of life studies in cystic fibrosis over the past 10 years have highlighted three key issues: the importance of patient-reported respiratory symptoms as an outcome measure for clinical trials; the growing perceptions among patients and families that the prescribed treatment regimen is burdensome²⁷⁷; and the significant differences in HRQOL by socioeconomic and racial/ethnic minority status. Indeed, prior research on HRQOL in cystic fibrosis has demonstrated that generic measures are insensitive, and that disease-specific tools are needed²⁷⁸. Efforts to develop reliable and valid HRQOL instruments in cystic fibrosis have been successful^{230, 271, 279} and are now routinely used in clinical trials of new medications and in studies of patient functioning. Currently, the most widely used HRQOL measure for cystic fibrosis is the CFQ-R (the Cystic Fibrosis Questionnaire-Revised; Box 3), with developmentally appropriate versions for preschoolers, school-aged children and their parents, and adolescents and adults²⁸⁰. The CFQ-R has been translated into more than 36 languages and is being used in several multinational trials.

Randomized controlled trials of new therapies in cystic fibrosis have used the CFQ-R as a primary or secondary outcome and have shown benefits in terms of reduction in respiratory symptoms and improvements in other domains, such as physical functioning, vitality and health perceptions^{230, 272, 274, 280}. Interestingly, improvements in respiratory symptoms have been found across trials of medications with very different mechanisms of actions (for example, inhaled antibiotics, hypertonic saline and potentiators), increasing confidence that this is an important outcome.

Although a primary reason that health outcomes and lifespan have improved dramatically over the past 20 years has been the development of new long-term therapies for patients with cystic fibrosis, treatment regimens now takes 2–3 hours per day for most patients²⁸⁰. In several studies using the CFQ-R, which has a treatment burden scale, patients and parents have reported increasing perceptions of burden^{275, 281}. In a recent, US epidemiological study over 3 years, both treatment complexity and perceived burden were highest among adults and those with severe lung disease, but increased in all age groups over the course of the study²⁸².

Using a national database in the United States, differences on the CFQ-R were shown by socioeconomic and racial/ethnic minority status. In a sample of 4,751 patients and 1,826 parents, after controlling for disease severity, people with low socioeconomic status reported significantly lower scores on the CFQ-R (children, parents and teen/adults) across the majority of domains. After controlling for both disease severity and socioeconomic status,

African-American and Hispanic families reported lower scores on the social and emotional functioning scales compared with their white counterparts²⁸³. These differences might be related to access to care, ability to afford medical insurance and other ancillary costs of optimal care (for example, good nutrition). Whether similar disparities are found in countries with national health care systems remains unclear.

Another important issue that affects HRQOL is comorbid depression and anxiety. Recently, an international psychological screening study of >6,000 patients with cystic fibrosis and 4,000 parent caregivers in nine countries found a significantly higher prevalence of these symptoms than in community samples²⁸⁴. Psychological distress has a direct negative effect on therapy adherence, attendance at clinic, hospitalizations and health care costs^{285–288}. As we move toward more patient-centred care, standardized assessments of HRQOL and psychological symptoms will be increasingly integrated into clinical care.

Outlook

Understanding the underlying genetic abnormalities and the mechanisms by which *CFTR* mutations cause disease has led to *CFTR*-specific therapies that are either already available to patients or close to clinical use (Figure 6). Additional compounds are being assessed in ongoing studies; thus, the armamentarium of treatment options will likely expand. Although genotype-specific therapy is being referred to as personalized medicine, it will not provide the same benefit to each patient. Some studies have already shown that response to interventions is not homogeneous even in patients carrying the same *CFTR* mutation²⁶³. Exploring modifier genes of involved intracellular pathways or other ion channels might help to better understand this variability and define additional therapeutic targets. In addition, current studies focus on patients with the *CFTR* mutations with known functional consequences on *CFTR* processing and function and will not be applicable to patients with rare mutations.

An individualized treatment approach will likely be needed for *CFTR*-directed pharmacotherapy, particularly for patients with rare or difficult to treat alleles. Individualized treatment will require test systems or biomarkers that have a high precision predicting treatment response. Potential assays could involve cells harvested from patients that can be used to test the most promising treatment combination *in vitro*. On the basis of their accessibility, nasal epithelial cells and intestinal cells transformed into organoids are currently being explored as potential models¹³⁵. Preliminary data using stem cells derived from skin fibroblasts or blood cells transformed into airway epithelial cells could offer an alternative in the near future²⁸⁹. Alternatives or additions to these *in vitro* assays could be to test drug response topically *in vivo* by applying them to the sweat gland or the nasal epithelium. In addition, sensitive clinical outcome measures will need to be developed to enable individual patient monitoring of drug response.

Ultimately, *CFTR*-directed therapy should prevent lung damage; to do so will require treatment early in disease process, ideally as soon as the diagnosis is established. Newborn screening offers a unique opportunity, but further work is needed to establish robust outcome measures in young children to provide evidence for efficacy of early treatment interventions.

Prevention of deterioration rather than improvements in disease manifestations will likely need to be the outcome measure of clinical trials in this age group. If this can be achieved, CFTR modulation could potentially maintain lung health and preserve lung function and structure. In addition, early application of CFTR modulators could also impact other disease manifestations, such as exocrine and endocrine pancreatic function. Conversely, in patients with established disease, the best scenario might be to transform cystic fibrosis into non-cystic fibrosis bronchiectasis — a disease that is much less severe but often still progressive. Thus, even with optimal CFTR-directed treatment, it will take decades until we can expect patients to not need treatment for the prominent disease manifestations of mucus obstruction, infection and inflammation. Although targeting CFTR is likely to make a major difference, finding better therapeutic strategies for these aspects of the disease will continue to be important to maintain lung health in patients with cystic fibrosis.

Acknowledgments

Competing interests

S.M.R. has received grants and/or non-financial support from: Cystic Fibrosis Foundation Therapeutics, the NIH, Vertex Pharmaceuticals, PTC Therapeutics, Novartis, Forest Research Institute, Bayer Healthcare and Galapagos.

C.H.G. has received grant funding and/or honoraria from: the NIH (grants P30 DK089507, R01HL103965, R01AI101307, UM1HL119073), FDA (grant R01FD003704), the Cystic Fibrosis Foundation, Vertex Pharmaceuticals, Transave Inc., L. Hoffmann- La Roche Ltd, Johns Hopkins University, the European CF Society, Medscape, and Gilead Sciences. He has also participated in Advisory Boards for KaloBios Pharmaceuticals and Transave Inc.

A.L.Q. has received grants and/or consulting income from: NIH (grant R01 DC04797), EU Health Commission (BESTCLIA), National Health and Medical Research Council of Australia, CFF Clinical Research Grant, Novartis, Abbott Pharmaceuticals, Vertex Pharmaceuticals, and Gilead Sciences.

F.R. has received grants and/or consulting fees from: the Canadian Institutes of Health Research, National Heart, Lung, and Blood Institute, the Cystic Fibrosis Foundation, Genentech, Vertex Pharmaceuticals, Novartis, Gilead Sciences, Boehringer Ingelheim, and Roche.

S.C.B. has received grants, personal fees, speaker's fees, and/or non-financial support from the National Health and Medical Research Council of Australia, the Cystic Fibrosis Foundation, the Office of Health and Medical Research, Queensland Health, the Queensland Children's Foundation, Vertex Pharmaceuticals, Novartis, and Gilead. He has served on advisory boards for Vertex Pharmaceuticals, Novartis, and Rempex and as a site PI in several clinical trials sponsored by Vertex Pharmaceuticals.

A.B. is supported by the UK NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.

References

1. Weiler CA & Drumm ML Genetic influences on cystic fibrosis lung disease severity. *Front Pharmacol* 4, 40 (2013). [PubMed: 23630497]
2. Jarvi K et al. Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia. *Lancet* 345, 1578 (1995). [PubMed: 7540706]
3. Gonska T et al. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. *Chest* 142, 996–1004 (2012). [PubMed: 22423042]
4. Wilschanski M et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. *Am J Respir Crit Care Med* 174, 787–94 (2006). [PubMed: 16840743]
5. Riordan JR et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 245, 1066–73 (1989). [PubMed: 2475911]

6. Rommens JM et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 245, 1059–65 (1989). [PubMed: 2772657]
7. Ratjen F & Grasemann H New therapies in cystic fibrosis. *Curr Pharm Des* 18, 614–27 (2012). [PubMed: 22229570]
8. O'Sullivan BP & Freedman SD Cystic fibrosis. *Lancet* 373, 1891–904 (2009). [PubMed: 19403164]
9. Walters S, M.A. in Hodson and Geddes' *Cystic Fibrosis* 3rd Ed. (ed. Hodson ME, Geddes DM, Bush A) 21–45 (Edward Arnold Ltd, London, 2007).
10. Farrell PM The prevalence of cystic fibrosis in the European Union. *J Cyst Fibros* 7, 450–3 (2008). [PubMed: 18442953]
11. Festini F et al. Incidence of cystic fibrosis in the Albanian population. *Pediatr Pulmonol* 43, 1124–9 (2008). [PubMed: 18972414]
12. Festini F, Taccetti G, Cioni ML, Repetto T & De Martino M High incidence of cystic fibrosis in children born in Italy to Albanian immigrants. *Thorax* 58, 93 (2003).
13. Dupuis A, Hamilton D, Cole DE & Corey M Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing. *J Pediatr* 147, 312–5 (2005). [PubMed: 16182667]
14. Kulich M, Rosenfeld M, Goss CH & Wilmott R Improved survival among young patients with cystic fibrosis. *J Pediatr* 142, 631–6 (2003). [PubMed: 12838190]
15. MacKenzie T et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. *Ann Intern Med* 161, 233–41 (2014). [PubMed: 25133359]
16. (© 2013 Cystic Fibrosis Foundation, Bethesda, Maryland, 2013).
17. Dodge JA, Lewis PA, Stanton M & Wilsher J Cystic fibrosis mortality and survival in the UK: 1947–2003. *Eur Respir J* 29, 522–6 (2007). [PubMed: 17182652]
18. Cystic Fibrosis Canada. (Toronto, Canada, 2010).
19. Kerem E et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. *Eur Respir J* 43, 125–33 (2014). [PubMed: 23598952]
20. Rodman DM et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. *Am J Respir Crit Care Med* 171, 621–6 (2005). [PubMed: 15591474]
21. Nick JA et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. *Am J Respir Crit Care Med* 182, 614–26 (2010). [PubMed: 20448091]
22. Simmonds NJ et al. Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function. *Eur Respir J* 37, 1076–82 (2011). [PubMed: 20847077]
23. George PM et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. *BMJ* 342, d1008 (2011). [PubMed: 21357627]
24. Accurso FJ et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. *N Engl J Med* 363, 1991–2003 (2010). [PubMed: 21083385]
25. Ramsey BW et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 365, 1663–72 (2011). [PubMed: 22047557]
26. Kerem B et al. Identification of the cystic fibrosis gene: genetic analysis. *Science* 245, 1073–80 (1989). [PubMed: 2570460]
27. Higgins CF ABC transporters: from microorganisms to man. *Annu Rev Cell Biol* 8, 67–113 (1992). [PubMed: 1282354]
28. Klein I, Sarkadi B & Varadi A An inventory of the human ABC proteins. *Biochim Biophys Acta* 1461, 237–62 (1999). [PubMed: 10581359]
29. Collins FS Cystic fibrosis: molecular biology and therapeutic implications. *Science* 256, 774–9 (1992). [PubMed: 1375392]
30. Serohijos AW et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. *Proc Natl Acad Sci U S A* 105, 3256–61 (2008). [PubMed: 18305154]
31. Drumm ML et al. Genetic modifiers of lung disease in cystic fibrosis. *N Engl J Med* 353, 1443–53 (2005). [PubMed: 16207846]

32. Chillon M et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. *N Engl J Med* 332, 1475–80 (1995). [PubMed: 7739684]
33. Sharer N et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. *N Engl J Med* 339, 645–52 (1998). [PubMed: 9725921]
34. Cohn JA et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. *N Engl J Med* 339, 653–8 (1998). [PubMed: 9725922]
35. Sosnay PR et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. *Nat Genet* 45, 1160–7 (2013). [PubMed: 23974870]
36. Welsh MJ & Smith AE Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Cell* 73, 1251–4 (1993). [PubMed: 7686820]
37. Clinical and Functional Translation of CFTR (CFTR2), <<http://www.cftr2.org>>.
38. Okiyoneda T et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. *Science* 329, 805–10 (2010). [PubMed: 20595578]
39. Mendoza JL et al. Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. *Cell* 148, 164–74 (2012). [PubMed: 22265409]
40. Rabeh WM et al. Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. *Cell* 148, 150–63 (2012). [PubMed: 22265408]
41. Green DM et al. Heritability of respiratory infection with *Pseudomonas aeruginosa* in cystic fibrosis. *J Pediatr* 161, 290–5 e1 (2012). [PubMed: 22364820]
42. Garred P et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. *J Clin Invest* 104, 431–7 (1999). [PubMed: 10449435]
43. Sun L et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. *Nat Genet* 44, 562–9 (2012). [PubMed: 22466613]
44. Blackman SM et al. Genetic modifiers of cystic fibrosis-related diabetes. *Diabetes* 62, 3627–35 (2013). [PubMed: 23670970]
45. Dorfman R et al. Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. *Hum Genet* 126, 763–78 (2009). [PubMed: 19662435]
46. Romi H et al. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C. *Am J Hum Genet* 90, 893–9 (2012). [PubMed: 22521417]
47. Li W et al. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. *Hum Genet* 133, 151–61 (2014). [PubMed: 24057835]
48. Wright FA et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. *Nat Genet* 43, 539–46 (2011). [PubMed: 21602797]
49. Collaco JM, Blackman SM, McGready J, Naughton KM & Cutting GR Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. *J Pediatr* 157, 802–7 e1–3 (2010). [PubMed: 20580019]
50. Vanscoy LL et al. Heritability of lung disease severity in cystic fibrosis. *Am J Respir Crit Care Med* 175, 1036–43 (2007). [PubMed: 17332481]
51. Kolbe EW et al. CLCA4 variants determine the manifestation of the cystic fibrosis basic defect in the intestine. *Eur J Hum Genet* 21, 691–4 (2013). [PubMed: 23073314]
52. Bremer LA et al. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. *Hum Mol Genet* 17, 2228–37 (2008). [PubMed: 18424453]
53. Yarden J et al. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. *Thorax* 60, 320–5 (2005). [PubMed: 15790988]
54. Goss CH, Newsom SA, Schildcrout JS, Sheppard L & Kaufman JD Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. *Am J Respir Crit Care Med* 169, 816–21 (2004). [PubMed: 14718248]
55. Collaco JM et al. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. *JAMA* 299, 417–24 (2008). [PubMed: 18230779]

56. Martin B et al. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. *Pediatrics* 129, e348–55 (2012). [PubMed: 22250024]
57. Boyle MP, Sabadosa KA, Quinton HB, Marshall BC & Schechter MS Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project. *BMJ Qual Saf* 23 Suppl 1, i15–i22 (2014).
58. Ooi CY & Durie PR Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. *J Cyst Fibros* 11, 355–62 (2012). [PubMed: 22658665]
59. Ratjen F & Doring G Cystic fibrosis. *Lancet* 361, 681–9 (2003). [PubMed: 12606185]
60. Rowe SM, Miller S & Sorscher EJ Cystic fibrosis. *N Engl J Med* 352, 1992–2001 (2005). [PubMed: 15888700]
61. Boucher RC Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. *Annual review of medicine* 58, 157–70 (2007).
62. Adebamiro A, Cheng Y, Rao US, Danahay H & Bridges RJ A segment of gamma ENaC mediates elastase activation of Na⁺ transport. *J Gen Physiol* 130, 611–29 (2007). [PubMed: 17998393]
63. Caldwell RA, Boucher RC & Stutts MJ Neutrophil elastase activates near-silent epithelial Na⁺ channels and increases airway epithelial Na⁺ transport. *Am J Physiol Lung Cell Mol Physiol* 288, L813–9 (2005). [PubMed: 15640288]
64. Passero CJ et al. TMPRSS4-dependent activation of the epithelial sodium channel requires cleavage of the gamma-subunit distal to the furin cleavage site. *Am J Physiol Renal Physiol* 302, F1–8 (2012). [PubMed: 21993886]
65. Matsui H et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. *Cell* 95, 1005–15 (1998). [PubMed: 9875854]
66. Button B et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. *Science* 337, 937–41 (2012). [PubMed: 22923574]
67. Chen JH et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. *Cell* 143, 911–23 (2010). [PubMed: 21145458]
68. Tuggle KL et al. Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats. *PLoS One* 9, e91253 (2014).
69. Itani OA et al. Human cystic fibrosis airway epithelia have reduced Cl⁻ conductance but not increased Na⁺ conductance. *Proc Natl Acad Sci U S A* 108, 10260–5 (2011). [PubMed: 21646513]
70. Birket SE et al. A functional anatomic defect of the cystic fibrosis airway. *Am J Respir Crit Care Med* 190, 421–32 (2014). [PubMed: 25029666]
71. Hoegger MJ et al. Cystic fibrosis. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. *Science* 345, 818–22 (2014). [PubMed: 25124441]
72. Corcoran TE et al. Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway. *Eur Respir J* 35, 781–6 (2010). [PubMed: 19717485]
73. Schutte A et al. Microbial-induced meprin beta cleavage in MUC2 mucin and a functional CFTR channel are required to release anchored small intestinal mucus. *Proc Natl Acad Sci U S A* 111, 12396–401 (2014). [PubMed: 25114233]
74. Henderson AG et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. *J Clin Invest* 124, 3047–60 (2014). [PubMed: 24892808]
75. Quinton PM Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. *Lancet* 372, 415–7 (2008). [PubMed: 18675692]
76. Garcia MA, Yang N & Quinton PM Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. *J Clin Invest* 119, 2613–22 (2009). [PubMed: 19726884]
77. Gustafsson JK et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. *J Exp Med* 209, 1263–72 (2012). [PubMed: 22711878]
78. Keiser NW et al. Defective Innate Immunity and Hyper-Inflammation in Newborn CFTR-Knockout Ferret Lungs. *Am J Respir Cell Mol Biol* (2014).

79. Rogers CS et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. *Science* 321, 1837–41 (2008). [PubMed: 18818360]
80. Kunzelmann K & Mehta A CFTR: a hub for kinases and crosstalk of cAMP and Ca²⁺. *FEBS J* 280, 4417–29 (2013). [PubMed: 23895508]
81. Garnett JP et al. Novel role for pendrin in orchestrating bicarbonate secretion in cystic fibrosis transmembrane conductance regulator (CFTR)-expressing airway serous cells. *J Biol Chem* 286, 41069–82 (2011).
82. Pezzulo AA et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. *Nature* 487, 109–13 (2012). [PubMed: 22763554]
83. Pohl K et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. *Blood* 124, 999–1009 (2014). [PubMed: 24934256]
84. Bruscia EM et al. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator^{-/-} mice. *Am J Respir Cell Mol Biol* 40, 295–304 (2009). [PubMed: 18776130]
85. Wang X et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. *Cell* 127, 803–15 (2006). [PubMed: 17110338]
86. Bedrossian C, Greenberg S, Singer D, Hansen J & Rosenberg H The lung in cystic fibrosis: a quantitative study including prevalence of pathologic findings among different age groups. *Hum Pathol* 7, 195–204. (1976). [PubMed: 1262016]
87. Livraghi-Butrico A et al. Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation. *Mucosal Immunol* 5, 397–408 (2012). [PubMed: 22419116]
88. Hybiske K et al. Effects of cystic fibrosis transmembrane conductance regulator and DeltaF508CFTR on inflammatory response, ER stress, and Ca²⁺ of airway epithelia. *Am J Physiol Lung Cell Mol Physiol* 293, L1250–60 (2007). [PubMed: 17827250]
89. Mott LS et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. *Thorax* (2011).
90. Sly PD et al. Risk factors for bronchiectasis in children with cystic fibrosis. *N Engl J Med* 368, 1963–70 (2013). [PubMed: 23692169]
91. Gehrig S et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. *Am J Respir Crit Care Med* 189, 1082–92 (2014). [PubMed: 24678594]
92. Vandivier RW et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. *J Clin Invest* 109, 661–70 (2002). [PubMed: 11877474]
93. Berger M, Sorensen RU, Tosi MF, Dearborn DG & Doring G Complement receptor expression on neutrophils at an inflammatory site, the *Pseudomonas*-infected lung in cystic fibrosis. *J Clin Invest* 84, 1302–13 (1989). [PubMed: 2507578]
94. Day BJ, van Heeckeren AM, Min E & Velsor LW Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary *pseudomonas* infection. *Infect Immun* 72, 2045–51 (2004). [PubMed: 15039325]
95. Roum JH, Buhl R, McElvaney NG, Borok Z & Crystal RG Systemic deficiency of glutathione in cystic fibrosis. *J Appl Physiol* (1985) 75, 2419–24 (1993). [PubMed: 8125859]
96. Knowles MR & Boucher RC Mucus clearance as a primary innate defense mechanism for mammalian airways. *J Clin Invest* 109, 571–7 (2002). [PubMed: 11877463]
97. Emerson J, Rosenfeld M, McNamara S, Ramsey B & Gibson RL *Pseudomonas aeruginosa* and other predictors of mortality and morbidity in young children with cystic fibrosis. *Pediatr Pulmonol* 34, 91–100 (2002). [PubMed: 12112774]
98. Nixon GM et al. Clinical outcome after early *Pseudomonas aeruginosa* infection in cystic fibrosis. *J Pediatr* 138, 699–704 (2001). [PubMed: 11343046]
99. Gangell C et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. *Clin Infect Dis* 53, 425–32 (2011). [PubMed: 21844026]

100. van Ewijk BE et al. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. *Pediatrics* 122, 1171–6 (2008). [PubMed: 19047230]
101. Wat D et al. The role of respiratory viruses in cystic fibrosis. *J Cyst Fibros* 7, 320–8 (2008). [PubMed: 18255355]
102. Wark PA et al. Viral infections trigger exacerbations of cystic fibrosis in adults and children. *Eur Respir J* 40, 510–2 (2012). [PubMed: 22855475]
103. Amin R, Dupuis A, Aaron SD & Ratjen F The effect of chronic infection with *Aspergillus fumigatus* on lung function and hospitalization in patients with cystic fibrosis. *Chest* 137, 171–6 (2010). [PubMed: 19567494]
104. Dasenbrook EC et al. Association between respiratory tract methicillin-resistant *Staphylococcus aureus* and survival in cystic fibrosis. *JAMA* 303, 2386–92 (2010). [PubMed: 20551409]
105. Govan JR, Brown AR & Jones AM Evolving epidemiology of *Pseudomonas aeruginosa* and the *Burkholderia cepacia* complex in cystic fibrosis lung infection. *Future Microbiol* 2, 153–64 (2007). [PubMed: 17661652]
106. Ledson MJ, Gallagher MJ, Jackson M, Hart CA & Walshaw MJ Outcome of *Burkholderia cepacia* colonisation in an adult cystic fibrosis centre. *Thorax* 57, 142–5 (2002). [PubMed: 11828044]
107. Aaron SD et al. Infection with transmissible strains of *Pseudomonas aeruginosa* and clinical outcomes in adults with cystic fibrosis. *JAMA* 304, 2145–53 (2010). [PubMed: 21081727]
108. Armstrong DS et al. Detection of a widespread clone of *Pseudomonas aeruginosa* in a pediatric cystic fibrosis clinic. *Am J Respir Crit Care Med* 166, 983–7 (2002). [PubMed: 12359658]
109. McCallum SJ et al. Superinfection with a transmissible strain of *Pseudomonas aeruginosa* in adults with cystic fibrosis chronically colonised by *P aeruginosa*. *Lancet* 358, 558–60 (2001). [PubMed: 11520530]
110. Cramer N et al. Molecular epidemiology of chronic *Pseudomonas aeruginosa* airway infections in cystic fibrosis. *PLoS One* 7, e50731 (2012).
111. Kidd TJ et al. *Pseudomonas aeruginosa* exhibits frequent recombination, but only a limited association between genotype and ecological setting. *PLoS One* 7, e44199 (2012).
112. Wiehlmann L et al. Effective prevention of *Pseudomonas aeruginosa* cross-infection at a cystic fibrosis centre - results of a 10-year prospective study. *Int J Med Microbiol* 302, 69–77 (2012). [PubMed: 22196973]
113. Griffiths AL et al. Effects of segregation on an epidemic *Pseudomonas aeruginosa* strain in a cystic fibrosis clinic. *Am J Respir Crit Care Med* 171, 1020–5 (2005). [PubMed: 15709051]
114. Adjemian J, Olivier KN & Prevots DR Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. *Am J Respir Crit Care Med* 190, 581–6 (2014). [PubMed: 25068291]
115. Qvist T et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. *J Cyst Fibros* (2014).
116. Bryant JM et al. Whole-genome sequencing to identify transmission of *Mycobacterium abscessus* between patients with cystic fibrosis: a retrospective cohort study. *Lancet* 381, 1551–60 (2013). [PubMed: 23541540]
117. Rogers GB et al. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. *J Clin Microbiol* 41, 3548–58 (2003). [PubMed: 12904354]
118. Tunney MM et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. *Am J Respir Crit Care Med* 177, 995–1001 (2008). [PubMed: 18263800]
119. LiPuma JJ Expanding our understanding of respiratory microbiota in cystic fibrosis. *Ann Am Thorac Soc* 11, 1084–5 (2014). [PubMed: 25237989]
120. Worlitzsch D et al. Effects of reduced mucus oxygen concentration in airway *Pseudomonas* infections of cystic fibrosis patients. *J Clin Invest* 109, 317–25 (2002). [PubMed: 11827991]
121. Bragonzi A et al. *Pseudomonas aeruginosa* microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. *Am J Respir Crit Care Med* 180, 138–45 (2009). [PubMed: 19423715]

122. Marvig RL, Sommer LM, Molin S & Johansen HK Convergent evolution and adaptation of *Pseudomonas aeruginosa* within patients with cystic fibrosis. *Nat Genet* 47, 57–64 (2015). [PubMed: 25401299]
123. Young RL et al. Neutrophil extracellular trap (NET)-mediated killing of *Pseudomonas aeruginosa*: evidence of acquired resistance within the CF airway, independent of CFTR. *PLoS One* 6, e23637 (2011).
124. Regamey N et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. *Thorax* 67, 164–70 (2012). [PubMed: 22008188]
125. Tan HL et al. The Th17 pathway in cystic fibrosis lung disease. *Am J Respir Crit Care Med* 184, 252–8 (2011). [PubMed: 21474644]
126. Hector A et al. Regulatory T Cell Impairment in Cystic Fibrosis Patients with Chronic *Pseudomonas* Infection. *Am J Respir Crit Care Med* (2015).
127. Ooi CY et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? *Thorax* 69, 254–60 (2014). [PubMed: 24149827]
128. Ooi CY et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language? *Thorax* 67, 618–24 (2012). [PubMed: 22504961]
129. Stewart B, Zabner J, Shuber AP, Welsh MJ & McCray PB Jr. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. *Am J Respir Crit Care Med* 151, 899–903 (1995). [PubMed: 7533604]
130. Knowles M, Gatz J & Boucher R Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. *N Engl J Med* 305, 1489–95 (1981). [PubMed: 7300874]
131. Ooi CY et al. Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis? *Ann Am Thorac Soc* 11, 562–70 (2014). [PubMed: 24697796]
132. Vermeulen F, Proesmans M, Boon M & De Boeck K Improved repeatability of nasal potential difference with a larger surface catheter. *J Cyst Fibros* (2014).
133. Veeze HJ, Sinaasappel M, Bijman J, Bouquet J & de Jonge HR Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. *Gastroenterology* 101, 398–403 (1991). [PubMed: 2065916]
134. Cohen-Cymberknob M et al. Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis. *Pediatr Pulmonol* 48, 229–35 (2013). [PubMed: 22553157]
135. Dekkers JF et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. *Nat Med* 19, 939–45 (2013) [PubMed: 23727931]
136. Quinton P et al. beta-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. *Am J Respir Crit Care Med* 186, 732–9 (2012). [PubMed: 22859523]
137. Lebecque P et al. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. *Am J Respir Crit Care Med* 165, 757–61 (2002). [PubMed: 11897640]
138. Bush A & Wallis C Time to think again: cystic fibrosis is not an “all or none” disease. *Pediatr Pulmonol* 30, 139–44 (2000). [PubMed: 10922136]
139. Sims EJ et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. *Lancet* 369, 1187–95 (2007). [PubMed: 17416263]
140. Farrell PM et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. *N Engl J Med* 337, 963–9 (1997). [PubMed: 9395429]
141. Wilcken B & Gaskin K More evidence to favour newborn screening for cystic fibrosis. *Lancet* 369, 1146–7 (2007). [PubMed: 17416243]
142. Balfour-Lynn IM Newborn screening for cystic fibrosis: evidence for benefit. *Arch Dis Child* 93, 7–10 (2008). [PubMed: 18156475]
143. Wagener JS, Zemanick ET & Sontag MK Newborn screening for cystic fibrosis. *Curr Opin Pediatr* 24, 329–35 (2012). [PubMed: 22491493]
144. Ranganathan SC et al. Airway function in infants newly diagnosed with cystic fibrosis. *Lancet* 358, 1964–5 (2001). [PubMed: 11747924]

145. Ranganathan SC et al. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. *Am J Respir Crit Care Med* 169, 928–33 (2004). [PubMed: 14754763]
146. Southern KW et al. A survey of newborn screening for cystic fibrosis in Europe. *J Cyst Fibros* 6, 57–65 (2007). [PubMed: 16870510]
147. Vernooij-van Langen AM et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. *Thorax* 67, 289–95 (2012). [PubMed: 22271776]
148. Southern KW Determining the optimal newborn screening protocol for cystic fibrosis. *Thorax* 67, 281–2 (2012). [PubMed: 22318162]
149. Roussey M et al. Neonatal screening of cystic fibrosis: diagnostic problems with CFTR mild mutations. *J Inherit Metab Dis* 30, 613 (2007). [PubMed: 17632692]
150. Scotet V et al. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels? *Pediatrics* 118, e1523–9 (2006). [PubMed: 17015492]
151. O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM & Parad R Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. *Pediatrics* 118, 1260–5 (2006). [PubMed: 16951024]
152. Peckham D, Conway SP, Morton A, Jones A & Webb K Delayed diagnosis of cystic fibrosis associated with R117H on a background of 7T polythymidine tract at intron 8. *J Cyst Fibros* 5, 63–5 (2006). [PubMed: 16266832]
153. de Nooijer RA et al. Assessment of CFTR function in homozygous R117H-7T subjects. *J Cyst Fibros* 10, 326–32 (2011). [PubMed: 21507732]
154. Cystic Fibrosis F et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. *J Pediatr* 155, S106–16 (2009). [PubMed: 19914443]
155. Mayell SJ et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. *J Cyst Fibros* 8, 71–8 (2009). [PubMed: 18957277]
156. Ren CL, Desai H, Platt M & Dixon M Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. *Pediatr Pulmonol* 46, 1079–84 (2011). [PubMed: 21538969]
157. Wielputz MO et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. *Am J Respir Crit Care Med* 189, 956–65 (2014). [PubMed: 24564281]
158. Aurora P et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. *Thorax* 59, 1068–73 (2004). [PubMed: 15563707]
159. Aurora P et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. *Am J Respir Crit Care Med* 171, 249–56 (2005). [PubMed: 15516530]
160. Kraemer R, Blum A, Schibler A, Ammann RA & Gallati S Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis. *Am J Respir Crit Care Med* 171, 371–8 (2005). [PubMed: 15531750]
161. Lum S et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. *Thorax* 62, 341–7 (2007). [PubMed: 17121870]
162. Hoo AF et al. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. *Thorax* 67, 874–81 (2012). [PubMed: 22752198]
163. Sly PD et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. *Am J Respir Crit Care Med* 180, 146–52 (2009). [PubMed: 19372250]
164. Pillarisetti N et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. *Am J Respir Crit Care Med* 184, 75–81 (2011). [PubMed: 21493738]
165. Nguyen TT et al. Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants. *Thorax* (2013).
166. Brennan LC et al. S7 Evolution of lung function during the first two years of life in infants with cystic fibrosis diagnosed by newborn screening. *Thorax* 68, A6–A7 (2013).

167. Amin R et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. *Eur Respir J* 37, 806–12 (2011). [PubMed: 20693248]
168. Amin R et al. Hypertonic saline improves the LCI in paediatric CF patients with normal lung function. *Thorax* 65, 379–383 (2010). [PubMed: 20435858]
169. Vermeulen F, Proesmans M, Boon M, Havermans T & De Boeck K Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. *Thorax* 69, 39–45 (2014). [PubMed: 24021874]
170. Maisonneuve P, Marshall BC, Knapp EA & Lowenfels AB Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. *J Natl Cancer Inst* 105, 122–9 (2013). [PubMed: 23178438]
171. Thia LP et al. Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age? *Thorax* 69, 320–7 (2014). [PubMed: 24132911]
172. Gustafsson PM, De Jong PA, Tiddens HA & Lindblad A Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. *Thorax* 63, 129–34 (2008). [PubMed: 17675316]
173. Owens CM et al. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. *Thorax* 66, 481–8 (2011). [PubMed: 21422040]
174. Stafler P, Davies JC, Balfour-Lynn IM, Rosenthal M & Bush A Bronchoscopy in cystic fibrosis infants diagnosed by newborn screening. *Pediatr Pulmonol* 46, 696–700 (2011). [PubMed: 21365781]
175. Wainwright CE et al. Effect of bronchoalveolar lavage-directed therapy on *Pseudomonas aeruginosa* infection and structural lung injury in children with cystic fibrosis: a randomized trial. *JAMA* 306, 163–71 (2011). [PubMed: 21750293]
176. King VV Upper respiratory disease, sinusitis, and polyposis. *Clin Rev Allergy* 9, 143–57 (1991). [PubMed: 1884322]
177. Henriksson G et al. Nasal polyps in cystic fibrosis: clinical endoscopic study with nasal lavage fluid analysis. *Chest* 121, 40–7 (2002). [PubMed: 11796430]
178. Hansen SK et al. Evolution and diversification of *Pseudomonas aeruginosa* in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. *ISME J* 6, 31–45 (2012). [PubMed: 21716309]
179. Rubinstein S, Moss R & Lewiston N Constipation and meconium ileus equivalent in patients with cystic fibrosis. *Pediatrics* 78, 473–9 (1986). [PubMed: 3748682]
180. Blondeau K et al. Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. *Gut* 57, 1049–55 (2008). [PubMed: 18372497]
181. Ledder O, Haller W, Couper RT, Lewindon P & Oliver M Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. *J Gastroenterol Hepatol* 29, 1954–62 (2014). [PubMed: 25238538]
182. Borowitz D et al. Gastrointestinal outcomes and confounders in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 41, 273–85 (2005). [PubMed: 16131979]
183. Lewindon PJ, Robb TA, Moore DJ, Davidson GP & Martin AJ Bowel dysfunction in cystic fibrosis: importance of breath testing. *J Paediatr Child Health* 34, 79–82 (1998). [PubMed: 9568948]
184. Konstan MW et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. *J Pediatr* 142, 624–30 (2003). [PubMed: 12838189]
185. Sharma R et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. *Thorax* 56, 746–50 (2001). [PubMed: 11562511]
186. Corbett K et al. Cystic fibrosis-associated liver disease: a population-based study. *J Pediatr* 145, 327–32 (2004). [PubMed: 15343185]
187. Rowland M et al. Outcome in cystic fibrosis liver disease. *Am J Gastroenterol* 106, 104–9 (2011). [PubMed: 20736939]
188. Moran A et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. *Diabetes Care* 33, 2697–708 (2010). [PubMed: 21115772]

189. Lewis C et al. Diabetes-related Mortality in Adults with Cystic Fibrosis. Role of Genotype and Sex. *Am J Respir Crit Care Med* 191, 194–200 (2015). [PubMed: 25479583]
190. Neinstein LS, Stewart D, Wang CI & Johnson I Menstrual dysfunction in cystic fibrosis. *J Adolesc Health Care* 4, 153–7 (1983). [PubMed: 6629971]
191. Stern M, Wiedemann B, Wenzlaff P & German Cystic Fibrosis Quality Assessment, G. From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995–2006. *Eur Respir J* 31, 29–35 (2008). [PubMed: 17898017]
192. Marshall BC & Nelson EC Accelerating implementation of biomedical research advances: critical elements of a successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative. *BMJ Qual Saf* 23 Suppl 1, i95–i103 (2014).
193. McCormick J et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. *Lancet* 375, 1007–13 (2010). [PubMed: 20304245]
194. Colombo C & Littlewood J The implementation of standards of care in Europe: state of the art. *J Cyst Fibros* 10 Suppl 2, S7–15 (2011). [PubMed: 21658645]
195. Stern M, Niemann N, Wiedemann B, Wenzlaff P & German CG Benchmarking improves quality in cystic fibrosis care: a pilot project involving 12 centres. *Int J Qual Health Care* 23, 349–56 (2011). [PubMed: 21504960]
196. Schechter MS Benchmarking to improve the quality of cystic fibrosis care. *Curr Opin Pulm Med* 18, 596–601 (2012). [PubMed: 22965277]
197. Conway S, B. -LI, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. *J Cyst Fibros* 13, S3–22 (2014). [PubMed: 24856776]
198. European Cystic Fibrosis Society. (Karup, Denmark, 2010).
199. Cystic Fibrosis Trust. (London, UK, 2013).
200. MacKenzie T, G. A, Sabadosa KA, Quinton HB, Knapp EA, Goss, Marshall BC Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. *Ann Intern Med* 161, 233–41 (2014). [PubMed: 25133359]
201. Goss CH et al. Children and young adults with CF in the USA have better lung function compared with the UK. *Thorax* (2014).
202. (Cystic Fibrosis Australia, Sydney, Australia, 2013).
203. Stern M et al. European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. *J Cyst Fibros* 13 Suppl 1, S43–59 (2014). [PubMed: 24856777]
204. Quittner AL et al. Pulmonary medication adherence and health-care use in cystic fibrosis. *Chest* 146, 142–51 (2014). [PubMed: 24480974]
205. Abbott J, Dodd M & Webb AK Health perceptions and treatment adherence in adults with cystic fibrosis. *Thorax* 51, 1233–8 (1996). [PubMed: 8994521]
206. Conway SP, Pond MN, Hamnett T & Watson A Compliance with treatment in adult patients with cystic fibrosis. *Thorax* 51, 29–33 (1996). [PubMed: 8658364]
207. Plant BJ, Goss CH, Plant WD & Bell SC Management of comorbidities in older patients with cystic fibrosis. *Lancet Respir Med* 1, 164–74 (2013). [PubMed: 24429097]
208. Grasemann H & Ratjen F Early lung disease in cystic fibrosis. *Lancet Respir Med* 1, 148–57 (2013). [PubMed: 24429095]
209. Flume PA et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am J Respir Crit Care Med* 180, 802–8 (2009). [PubMed: 19729669]
210. Smyth AR et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. *J Cyst Fibros* 13 Suppl 1, S23–42 (2014). [PubMed: 24856775]
211. Okumura MJ et al. Improving transition from paediatric to adult cystic fibrosis care: programme implementation and evaluation. *BMJ Qual Saf* 23 Suppl 1, i64–i72 (2014).
212. Lester MK & Flume PA Airway-clearance therapy guidelines and implementation. *Respir Care* 54, 733–50; discussion 751–3 (2009). [PubMed: 19467161]

213. McIlwaine MP et al. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. *Thorax* 68, 746–51 (2013). [PubMed: 23407019]
214. Schneiderman JE et al. Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. *Eur Respir J* 43, 817–23 (2014). [PubMed: 24176992]
215. Cox NS, Alison JA & Holland AE Interventions for promoting physical activity in people with cystic fibrosis. *Cochrane Database Syst Rev* 12, CD009448 (2013).
216. Fuchs HJ et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. *N Engl J Med* 331, 637–42 (1994). [PubMed: 7503821]
217. Jones AP & Wallis CE Recombinant human deoxyribonuclease for cystic fibrosis. *Cochrane Database Syst Rev*, CD001127 (2003).
218. Shah PI et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. *Eur Respir J* 8, 954–8 (1995). [PubMed: 7589382]
219. Quan JM et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. *J Pediatr* 139, 813–20 (2001). [PubMed: 11743506]
220. Flume PA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. *Am J Respir Crit Care Med* 176, 957–69 (2007). [PubMed: 17761616]
221. Elkins MR et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. *N Engl J Med* 354, 229–40 (2006). [PubMed: 16421364]
222. Rosenfeld M et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. *JAMA* 307, 2269–77 (2012). [PubMed: 22610452]
223. Subbarao P et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. *Am J Respir Crit Care Med* 188, 456–60 (2013). [PubMed: 23742699]
224. Bilton D et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. *Eur Respir J* 38, 1071–80 (2011). [PubMed: 21478216]
225. Aitken ML et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. *Am J Respir Crit Care Med* 185, 645–52 (2012). [PubMed: 22198974]
226. Ramsey BW et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. *N Engl J Med* 328, 1740–6 (1993). [PubMed: 8497284]
227. Ramsey BW et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. *N Engl J Med* 340, 23–30 (1999). [PubMed: 9878641]
228. Konstan MW et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. *J Cyst Fibros* 10, 54–61 (2011). [PubMed: 21075062]
229. McCoy KS et al. Inhaled aztreonam lysine for chronic airway *Pseudomonas aeruginosa* in cystic fibrosis. *Am J Respir Crit Care Med* 178, 921–8 (2008). [PubMed: 18658109]
230. Retsch-Bogart GZ et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and *Pseudomonas aeruginosa* infection. *Pediatr Pulmonol* 43, 47–58 (2008). [PubMed: 18041081]
231. Doring G, Flume P, Heijerman H, Elborn JS & Consensus Study G Treatment of lung infection in patients with cystic fibrosis: current and future strategies. *J Cyst Fibros* 11, 461–79 (2012). [PubMed: 23137712]
232. Tullis DE et al. Inhaled aztreonam for chronic *Burkholderia* infection in cystic fibrosis: a placebo-controlled trial. *J Cyst Fibros* 13, 296–305 (2014). [PubMed: 24176390]
233. Wolter J et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. *Thorax* 57, 212–6 (2002). [PubMed: 11867823]
234. Saiman L et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 290, 1749–56 (2003). [PubMed: 14519709]

235. Saiman L et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 303, 1707–15 (2010). [PubMed: 20442386]
236. Clement A et al. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. *Thorax* 61, 895–902 (2006). [PubMed: 16809416]
237. Konstan MW, Byard PJ, Hoppel CL & Davis PB Effect of high-dose ibuprofen in patients with cystic fibrosis. *N Engl J Med* 332, 848–54 (1995). [PubMed: 7503838]
238. Lands LC & Stanojevic S Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. *Cochrane Database Syst Rev* 6, CD001505 (2013).
239. Auerbach HS, Williams M, Kirkpatrick JA & Colten HR Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. *Lancet* 2, 686–8 (1985). [PubMed: 2863676]
240. Eigen H, Rosenstein BJ, FitzSimmons S & Schidlow DV A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. *J Pediatr* 126, 515–23 (1995). [PubMed: 7699528]
241. Balfour-Lynn IM & Welch K Inhaled corticosteroids for cystic fibrosis. *Cochrane Database Syst Rev*, CD001915 (2009).
242. Balfour-Lynn IM et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. *Am J Respir Crit Care Med* 173, 1356–62 (2006). [PubMed: 16556691]
243. Konstan MW et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB₄ receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. *J Cyst Fibros* 13, 148–55 (2014). [PubMed: 24440167]
244. Hirche TO et al. Practical guidelines: lung transplantation in patients with cystic fibrosis. *Pulm Med* 2014, 621342 (2014). [PubMed: 24800072]
245. Madden BP et al. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. *Eur Respir J* 19, 310–3 (2002). [PubMed: 11866011]
246. Gill DR & Hyde SC Delivery of genes into the CF airway. *Thorax* 69, 962–4 (2014). [PubMed: 25015239]
247. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. *Nat Genet* 8, 42–51 (1994). [PubMed: 7527271]
248. Harvey BG, Hackett NR, Ely S & Crystal RG Host responses and persistence of vector genome following intrabronchial administration of an E1(–)E3(–) adenovirus gene transfer vector to normal individuals. *Mol Ther* 3, 206–15 (2001). [PubMed: 11237677]
249. Knowles MR et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. *N Engl J Med* 333, 823–31 (1995). [PubMed: 7544439]
250. Moss RB et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. *Chest* 125, 509–21 (2004). [PubMed: 14769732]
251. Moss RB et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. *Hum Gene Ther* 18, 726–32 (2007). [PubMed: 17685853]
252. Griesenbach U et al. Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. *Am J Respir Crit Care Med* 186, 846–56 (2012). [PubMed: 22955314]
253. Alton EW et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. *Thorax* 68, 1075–7 (2013). [PubMed: 23525080]
254. Bangel-Ruland N et al. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy. *J Gene Med* 15, 414–26 (2013). [PubMed: 24123772]
255. Wilschanski M et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. *N Engl J Med* 349, 1433–41 (2003). [PubMed: 14534336]

256. Linde L et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. *J Clin Invest* 117, 683–92 (2007). [PubMed: 17290305]
257. Kerem E et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Respir Med* 2, 539–47 (2014). [PubMed: 24836205]
258. Van Goor F, Hadida S, Grootenhuis P & al., e. Rescue of CF airway epithelial cell function invitro by a CFTR potentiator, VX-770. . *Proc Natl Acad Sci USA* 106, 18825–30 (2009). [PubMed: 19846789]
259. Rowe SM et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. *Am J Respir Crit Care Med* 190, 175–84 (2014). [PubMed: 24927234]
260. De Boeck K et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. *J Cyst Fibros* (2014).
261. Sloane PA et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. *PLoS One* 7, e39809 (2012).
262. Flume PA et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. *Chest* 142, 718–24 (2012). [PubMed: 22383668]
263. Boyle MP, B. S, Konstan MW, McColley SA, Rowe SM, Rietschel, Huang X, Waltz D, Patel NR, Rodman D; VX09–809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. *Lancet Respir Med*. 2, 527–38 (2014). [PubMed: 24973281]
264. Van Goor F, H. S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *Proc Natl Acad Sci U S A*. 108, 18843–8 (2011). [PubMed: 21976485]
265. Veit G, A. R, Perdomo D, Phuan PW, Bagdany M, Apaja PM, Borot F, Szollosi D, Wu YS, Finkbeiner WE, Hegedus T, Verkman, Lukacs GL Some gating potentiators, including VX-770, diminish F508-CFTR functional expression. *Sci Transl Med*. 6, 246ra97 (2014).
266. Cholon DM, Q. N, Fulcher ML, Esther CR Jr, Das, Dokholyan NV, Randell SH, Boucher RC, Gentzsch M Potentiator ivacaftor abrogates pharmacological correction of F508 CFTR in cystic fibrosis. *Sci Transl Med*. 6, 246ra96 (2014).
267. Okiyonedo T et al. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. *Nat Chem Biol* 9, 444–54 (2013). [PubMed: 23666117]
268. Accurso FJ et al. Denufosal tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. *Am J Respir Crit Care Med* 183, 627–34 (2011). [PubMed: 21169471]
269. Ratjen F et al. Long term effects of denufosal tetrasodium in patients with cystic fibrosis. *J Cyst Fibros* 11, 539–49 (2012). [PubMed: 22682898]
270. Burrows EF, Southern KW & Noone PG Sodium channel blockers for cystic fibrosis. *Cochrane Database Syst Rev* 4, CD005087 (2014).
271. Quittner AL, Alpern AN, Kimberg CI in Kendig & Chernick's Disorders of the Respiratory Tract in Children 251–260 (2012).
272. Goss CH, Edwards TC, Ramsey BW, Aitken ML & Patrick DL Patient-reported respiratory symptoms in cystic fibrosis. *J Cyst Fibros* 8, 245–52 (2009). [PubMed: 19481983]
273. Schmidt AM et al. Exercise and quality of life in patients with cystic fibrosis: A 12-week intervention study. *Physiother Theory Pract* 27, 548–56 (2011). [PubMed: 21722067]
274. Schechter MS et al. Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis. *Ann Am Thorac Soc* 10, 213–9 (2013). [PubMed: 23802817]
275. Sawicki GS et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. *Pediatr Pulmonol* 46, 36–44 (2011). [PubMed: 20848580]
276. Snyder CF et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. *Qual Life Res* 21, 1305–14 (2012). [PubMed: 22048932]
277. Sawicki GS, Sellers DE & Robinson WM High treatment burden in adults with cystic fibrosis: challenges to disease self-management. *J Cyst Fibros* 8, 91–6 (2009). [PubMed: 18952504]

278. Quittner AL Measurement of quality of life in cystic fibrosis. *Curr Opin Pulm Med* 4, 326–31 (1998). [PubMed: 10813210]
279. Goss CH & Quittner AL Patient-reported outcomes in cystic fibrosis. *Proc Am Thorac Soc* 4, 378–86 (2007). [PubMed: 17652505]
280. Quittner AL et al. Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. *Qual Life Res* 21, 1279–90 (2012). [PubMed: 22240933]
281. Donaldson SH et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. *N Engl J Med* 354, 241–50 (2006). [PubMed: 16421365]
282. Sawicki GS et al. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. *J Cyst Fibros* 12, 461–7 (2013). [PubMed: 23352205]
283. Quittner AL et al. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. *Chest* 137, 642–50 (2010). [PubMed: 19820076]
284. Quittner AL et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. *Thorax* 69, 1090–7 (2014). [PubMed: 25246663]
285. Smith BA, Modi AC, Quittner AL & Wood BL Depressive symptoms in children with cystic fibrosis and parents and its effects on adherence to airway clearance. *Pediatr Pulmonol* 45, 756–63 (2010). [PubMed: 20597082]
286. Riekert KA, Bartlett SJ, Boyle MP, Krishnan JA & Rand CS The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. *Chest* 132, 231–7 (2007). [PubMed: 17625085]
287. Goldbeck L et al. Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis. *Chest* 138, 929–36 (2010). [PubMed: 20472857]
288. Snell C, Fernandes S, Bujoreanu IS & Garcia G Depression, illness severity, and healthcare utilization in cystic fibrosis. *Pediatr Pulmonol* 49, 1177–81 (2014). [PubMed: 24619910]
289. Wong AP et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. *Nat Biotechnol* 30, 876–82 (2012).. [PubMed: 22922672]

Box 1 |**Phenotypes of cystic fibrosis**

Classic cystic fibrosis

- Chronic sinusitis
- Pancreatic insufficiency
- Diabetes
- Obstructive lung disease from infancy with chronic bacterial infection
- Severe liver disease (5–10% of patients)
- Meconium ileus (15–20 % of patients)
- Congenital bilateral absence of vas deference (males)
- High sweat chloride concentrations

Nonclassic cystic fibrosis

- Chronic sinusitis
- Pancreatic sufficiency
- Pancreatitis (5–20%)
- Obstructive lung disease (variable onset)
- Congenital bilateral absence of vas deference (males)
- Lower sweat chloride concentrations than classic cystic fibrosis

Box 2 |**Conventional diagnostic criteria for cystic fibrosis**

Individuals must have at least one clinical feature:

- meconium ileus
- diarrhoea and failure to thrive
- recurrent respiratory infections
- nasal polyps
- rectal prolapse
- male infertility
- electrolyte depletion

or a diagnosis of cystic fibrosis in a sibling or a positive newborn screening test plus laboratory evidence of an abnormality in the CFTR gene or protein:

- chloride channel dysfunction (positive sweat test or abnormal transepithelial potential difference)
- known disease-causing mutations on chromosome 7 in *trans*

Box 3 |**Domains on the Cystic Fibrosis Questionnaire-Revised (CFQ-R)**

Functional and psychosocial scales

- Physical functioning: ability to walk, climb stairs, carry heavy items; ability to run, jump and play
- Social and school functioning: going out with friends, engaging in social activities
- Emotional functioning: feeling happy, sad, worried
- Treatment burden: time spent on treatments, fitting treatments into daily activities
- Eating problems: challenges eating and making calorie goals
- Body image: physical appearance, being short or thin
- Vitality*: energy level, extent of fatigue
- Health perceptions*: perceptions of current health and disease severity
- Role functioning*: ability to perform daily activities (attending school, working, household tasks)

Symptom Scales

- Respiratory symptoms: frequency and severity of cough, mucus production, chest congestion
- Digestive symptoms: frequency and severity of abdominal pain, stools, gas
- Sinus symptoms: frequency and severity of sinus headaches, nasal congestion, postnasal drip
- Weight*: perception of current weight

* Not administered to children ages 6–13 years of age

Figure 1.

Cystic fibrosis in the United States. a | The number of patients reported in the annual reports of the CF Foundation in 5 year intervals from 1998 to 2013. The figure notes a fairly substantial increase in the number of people living with cystic fibrosis in the US CFF Patient Registry, which is likely attributable to improved survival of patients during this 15 year period and not merely newly diagnosed patients. b | The numbers of newly diagnosed patients in each of the given years over time.

Figure 2.

Structure of CFTR. a | Linear structure of the protein. b | The cystic fibrosis transmembrane conductance regulator (CFTR) protein is comprised of two, six span membrane-bound regions each connected to a nuclear binding domain (NBD1 and NBD2), which bind ATP, as well as a regulatory (R) domain that is comprised of many charged amino acids. The channel opens when its R-domain is phosphorylated by protein kinase A and ATP is bound at the NBDs.

Figure 3. The mucociliary transport defect in cystic fibrosis.

a | In the healthy state, adequate airway surface homeostasis enables effective transport of mucus extruding from the airway surface goblet cells and submucosal glands. Appropriate bicarbonate and pH regulation enable normal mucus to form, which facilitates the formation of a two-layer gel that optimizes mucociliary clearance and airway defence. b | Depletion of the airway surface liquid occurs through the absence of cystic fibrosis transmembrane conductance regulator (CFTR)-mediated fluid secretion accompanied by tonic fluid absorption via the epithelial sodium channel (ENaC; inset). CFTR-dependent liquid desiccation decreases airway surface liquid (ASL) depth including the periciliary layer (PCL), ultimately contributing to mucus stasis. Decreased bicarbonate transport contributes to an acidic pH. Abnormally adherent mucus also emerges from the glands in cystic fibrosis, and can become fixed to the gland orifice or the originating goblet cells. These events contribute to a proinflammatory airway environment that further accelerates pathogenesis.

Figure 4. Diagnosing cystic fibrosis: nasal potential difference measurement.

Representative nasal potential difference tracings from a healthy control (blue) and a patient with cystic fibrosis (red). The nasal mucosa is sequentially perfused with Ringer's solution (an isotonic solution relative to the bodily fluids), Ringer's solution with amiloride to block the epithelial sodium channel (ENaC), chloride-free solution with amiloride, chloride-free solution with amiloride and isoproterenol to activate the cystic fibrosis transmembrane conductance regulator (CFTR), and finally the addition of ATP to activate non-CFTR-dependent anion transport. The change in potential difference upon addition of amiloride is used to estimate sodium transport, which is elevated in cystic fibrosis. The change in potential difference with chloride-free isoproterenol is used to measure CFTR-dependent anion transport, which is reduced in cystic fibrosis. Patients with mild phenotypes of cystic fibrosis generally exhibit intermediate results.

Figure 5. Currently available therapies to treat patients with cystic fibrosis.

Although the therapies are based on the cellular mechanism, the details on how these compounds exert their effects at the molecular level are not entirely clear for most drugs, a consequence of their identification from high-throughput screening programmes that focus on the functional readout rather than mechanism of action. Most compounds generally address a specific aspect of the molecular defect and do not, therefore, alleviate the effects of all classes of *CFTR* mutations. For example, the *CFTR* potentiator ivacaftor directly activates *CFTR* and is currently licensed in most countries (except New Zealand) for patients with class III (gating) mutations. Hypertonic saline increases airway surface liquid, which is reduced in patients with cystic fibrosis as a consequence of defective chloride and increased sodium absorption. Dornase alfa cleaves extracellular DNA, thereby reducing the viscosity of airway secretions. Inhaled tobramycin and aztreonam are used as chronic maintenance therapy in patients with chronic *Pseudomonas aeruginosa* infection. Azithromycin has multiple potential modes of action, but mainly ameliorates airway inflammation — as is the case for high dose ibuprofen, which reduces neutrophil influx into the airways.

Figure 6. Emerging approaches to address the ion channel abnormalities in cystic fibrosis. The main target for therapeutics is cystic fibrosis transmembrane conductance regulator (CFTR), which can be replaced through gene therapy, or increased in concentration on the cell surface. Increased CFTR concentration could be achieved through translational readthrough therapy (class I mutations), correction of intracellular trafficking (class II mutations) or potentiation of its function (class III mutations, potentially class IV and class V). Alternatively, a calcium-activated chloride channel could be a therapeutic target; this channel is activated through the P2Y2 receptor (the natural ligand being ATP). Finally, as sodium absorption is upregulated in the airways of patients with cystic fibrosis, blocking the epithelial sodium channel (ENaC) could be of benefit to increase airway surface liquid.

Table 1.*CFTR* mutations by molecular class, functional abnormality and primary therapy type

Molecular classification	Functional abnormality	Molecular consequence	Primary therapy type	Example mutations
Class I	Decreased number	No functional protein produced	Translational readthrough *	G542X, 394delTT, 3905insT
Class II	Decreased number	Absent or diminished protein processing	Corrector * Potentiator * ‡	F508del, N1303K, A455E
Class III	Decreased function [§]	Defective gating	Potentiator *	G551D, R117H, F508del [‡]
Class IV	Decreased function	Decreased conductance	Potentiator *	R347H, R334W, R117H [‡]
Class V	Decreased number	Abnormal splicing (canonical [complete] or noncanonical [partial])	Splice repair // Potentiator //	621+1G>T, 3849+10kbC>T, R117H+5T
Class VI	Decreased number	Decreased cell surface stability	Cell surface stabilizer // Potentiator //	S1455X, L1399X, F508del [‡]

* Therapy type that has shown activity in one or more clinical trials.

‡ Secondary abnormality.

[§] Open channel probability.

// Potential therapy type.